USRE43901E1 - Apparatus for controlling thermal dosing in a thermal treatment system - Google Patents

Apparatus for controlling thermal dosing in a thermal treatment system Download PDF

Info

Publication number
USRE43901E1
USRE43901E1 US11/223,907 US22390705A USRE43901E US RE43901 E1 USRE43901 E1 US RE43901E1 US 22390705 A US22390705 A US 22390705A US RE43901 E USRE43901 E US RE43901E
Authority
US
United States
Prior art keywords
thermal dose
treatment
thermal
properties
treatment plan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime, expires
Application number
US11/223,907
Inventor
David Freundlich
Jacob Vortman
Roni Yagel
Shuki Vitek
Naama Brenner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insightec Ltd
Original Assignee
Insightec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insightec Ltd filed Critical Insightec Ltd
Priority to US11/223,907 priority Critical patent/USRE43901E1/en
Application granted granted Critical
Publication of USRE43901E1 publication Critical patent/USRE43901E1/en
Adjusted expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00Ultrasound therapy
    • A61N7/02Localised ultrasound hyperthermia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00017Electrical control of surgical instruments
    • A61B2017/00022Sensing or detecting at the treatment site
    • A61B2017/00084Temperature
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/36Image-producing devices or illumination devices not otherwise provided for
    • A61B90/37Surgical systems with images on a monitor during operation
    • A61B2090/374NMR or MRI
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B34/00Computer-aided surgery; Manipulators or robots specially adapted for use in surgery
    • A61B34/10Computer-aided planning, simulation or modelling of surgical operations

Definitions

  • the present invention relates generally to thermal treatment systems, and more particularly to a method and apparatus for controlling thermal dosing in a thermal treatment system.
  • Thermal energy such as generated by high intensity focused ultrasonic waves (acoustic waves with a frequency greater than about 20 kilohertz), may be used to therapeutically treat internal tissue regions within a patient.
  • ultrasonic waves may be used to ablate tumors, thereby obviating the need for invasive surgery.
  • piezoelectric transducers driven by electric signals to produce ultrasonic energy have been suggested that may be placed external to the patient but in close proximity to the tissue to be ablated.
  • the transducer is geometrically shaped and positioned such that the ultrasonic energy is focused at a “focal zone” corresponding to a target tissue region within the patient, heating the target tissue region until the tissue is coagulated.
  • the transducer may be sequentially focused and activated at a number of focal zones in close proximity to one another. This series of “sonications” is used to cause coagulation necrosis of an entire tissue structure, such as a tumor, of a desired size and shape.
  • the transducer is preferably geometrically shaped and positioned so that the ultrasonic energy is focused at a “focal zone” corresponding to the target tissue region, heating the region until the tissue is necrosed.
  • the transducer may be sequentially focused and activated at a number of focal zones in close proximity to one another. For example, this series of “sonications” may be used to cause coagulation necrosis of an entire tissue structure, such as a tumor, of a desired size and shape.
  • FIG. 1A depicts a phased array transducer 10 having a “spherical cap” shape.
  • the transducer 10 includes a plurality of concentric rings 12 disposed on a curved surface having a radius of curvature defining a portion of a sphere.
  • the concentric rings 12 generally have equal surface areas and may also be divided circumferentially 14 into a plurality of curved transducer sectors, or elements 16 , creating a “tiling” of the face of the transducer 10 .
  • the transducer elements 16 are constructed of a piezoelectric material such that, upon being driven with a sinus wave near the resonant frequency of the piezoelectric material, the elements 16 vibrate according to the phase and amplitude of the exciting sinus wave, thereby creating the desired ultrasonic wave energy.
  • the phase shift and amplitude of the respective sinus “drive signal” for each transducer element 16 is individually controlled so as to sum the emitted ultrasonic wave energy 18 at a focal zone 20 having a desired mode of focused planar and volumetric pattern. This is accomplished by coordinating the signal phase of the respective transducer elements 16 in such a manner that they constructively interfere at specific locations, and destructively cancel at other locations. For example, if each of the elements 16 are driven with drive signals that are in phase with one another, (known as “mode 0 ”), the emitted ultrasonic wave energy 18 are focused at a relatively narrow focal zone.
  • mode 0 drive signals that are in phase with one another
  • the elements 16 may be driven with respective drive signals that are in a predetermined shifted-phase relationship with one another (referred to in U.S. Pat. No. 4,865,042 to Umemura et al. as “mode n”).
  • mode n a predetermined shifted-phase relationship with one another
  • Multiple shapes of the focal spot can be created by controlling the relative phases and amplitudes of the emmitted energy from the array, including steering and scanning of the beam, enabling electronic control of the focused beam to cover and treat multiple of spots in the defined zone of a defined tumor inside the body.
  • a cooling period is required to avoid harmful and painful heat build up in healthy tissue adjacent a target tissue structure.
  • This cooling period may be significantly longer than the thermal dosing period. Since a large number of sonications may be required in order to fully ablate the target tissue site, the overall time required can be significant. If the procedure is MRI-guided, this means that the patient must remain motionless in a MRI machine for a significant period of time, which can be very stressful. At the same time, it may be critical that the entire target tissue structure be ablated (such as, e.g., in the case of a malignant cancer tumor), and that the procedure not take any short cuts just in the name of patient comfort.
  • thermal energy such as focused ultrasound energy
  • a thermal treatment system including a heat applying element for generating a thermal dose used to ablate a target mass in a patient, a controller for controlling thermal dose properties of the heat applying element, an imager for providing preliminary images of the target mass and thermal images during the treatment, and a planner for automatically constructing a treatment plan, comprising a series of treatment sites that are each represented by a set of thermal dose properties.
  • the heat applying element may apply any of ultrasound energy, laser light energy, radio frequency (RF) energy, microwave energy, or electrical energy.
  • the planner automatically constructs the treatment plan based on input information including one or more of a volume of the target mass, a distance from a skin surface of the patient to the target mass, a set of default thermal dose prediction properties, a set of user specified thermal dose prediction properties, physical properties of the heat applying elements, and images provided by the imager.
  • the default thermal dose prediction properties are preferably based on a type of clinical application and include at least one of thermal dose threshold, thermal dose prediction algorithm, maximum allowed energy for each thermal dose, thermal dose duration for each treatment site, cooling time between thermal doses, and electrical properties for the heat applying element.
  • the user specified thermal dose prediction properties preferably include at least one or more of overrides for any default thermal dose prediction properties, treatment site grid density; and thermal dose prediction properties not specified as default thermal dose prediction properties from the group comprised of thermal dose threshold, thermal dose prediction algorithm, maximum allowed energy for each thermal dose, thermal dose duration for each treatment site cooling time between thermal doses, and electrical properties for the heat applying element.
  • the treatment plan ensures that the entire target mass is covered by a series of thermal doses so as to obtain a composite thermal dose sufficient to ablate the entire target mass, and the thermal dose properties are automatically optimized using physiological properties as the optimization criterion.
  • the planner limits the thermal dose at each treatment site in order to prevent evaporation or carbonization.
  • the planner constructs a predicted thermal dose distribution in three dimensions, illustrating the predicted thermal dose threshold contours of each treatment site in the treatment plan.
  • a User Interface may also be provided for entering user specified thermal dose prediction properties and for editing the treatment plan once the treatment plan is constructed.
  • a feedback imager for providing thermal images may also be provided, wherein the thermal images illustrate the actual thermal dose distribution resulting at each treatment site. In one embodiment, the imager acts as the feedback imager.
  • the imager provides outlines of sensitive regions within the patient where ultrasonic waves are not allowed to pass, wherein the processor uses the outlines in constructing the treatment plan so as to avoid exposing the sensitive regions to ultrasound.
  • a method of controlling thermal dosing in a thermal treatment system includes selecting an appropriate clinical application protocol, the selected application protocol having associated with it certain default thermal dosing properties; retrieving relevant magnetic resonant images for thermal dose planning; tracing a target mass on the images; entering user specified thermal dosing properties and selectively modifying the default thermal dosing properties; and automatically constructing a treatment plan representing thermal doses to be applied to treatment sites, the treatment plan based on the default thermal dosing properties and the user specified thermal dosing properties.
  • tracing the target mass can be done manually or automatically, and may include evaluating the target mass to ensure that obstacles including bones, gas, or other sensitive tissue will not interfere with the thermal doses and repositioning a patient or a heat applying element in order to bypass any such obstacles.
  • the treatment plan ensures that a target mass receives a composite thermal dose sufficient to ablate the target mass, wherein automatically constructing the treatment plan includes predicting and displaying a predicted thermal dose distribution.
  • automatically constructing the treatment plan further includes calculating limits for each thermal dose to be applied to each treatment site in order to prevent evaporation or carbonation.
  • the treatment plan may be manually edited, including at least one of adding treatment sites, deleting treatment sites, changing the location of treatment sites, changing thermal dosing properties, and reconstructing the entire treatment plan with new thermal dosing properties.
  • FIG. 1B is a partially cut-away side view of the transducer of FIG. 1A , illustrating the concentrated emission of focused ultrasonic energy in a targeted focal region.
  • FIG. 2 is simplified schematic block diagram of a thermal treatment system for providing thermal energy dosing of a target tissue region in a patient.
  • FIG. 3 is a cross-sectional view of an ultrasonic transducer and target tissue mass to be treated in a preferred embodiment of the system of FIG. 2 .
  • FIG. 5 is a preferred process flow diagram for constructing a three-dimensional treatment plan using the system of FIG. 2 .
  • FIG. 6 is a simplified schematic block diagram of an alternate thermal treatment system comprising a feedback image generator.
  • FIGS. 7A and 7B are two-dimensional representations of a target sonication areas, illustrating instances in which the actual thermal ablation is either greater than ( FIG. 7A ), or less than ( FIG. 7B ), the predicted amount.
  • FIG. 8 illustrates a comparison of actual versus predicted thermal doses for an entire target tissue region constructed by the system of FIG. 6 using images from the feedback image generator.
  • FIG. 9 illustrates a preferred method of controlling thermal dosing in a thermal treatment system.
  • FIG. 10A illustrates a two dimensional pixel representation of a predicted thermal dose to be applied to a target tissue region.
  • FIG. 10B illustrates a two dimensional pixel representation of an actual thermal dose resulting from a thermal treatment intended to result in the predicted thermal dose of FIG. 10A .
  • FIG. 10C illustrates a two dimensional pixel representation of a remaining untreated target tissue region derived by subtracting the pixel representation of FIG. 10B from the pixel representation of FIG. 10A .
  • FIG. 11 illustrates a preferred method for updating a thermal treatment plan.
  • the invention will now be illustrated by examples that use an ultrasound transducer as the means of delivering energy to a target mass. It will be apparent to those skilled in the art, however, that other energy delivery vehicles can be used.
  • the invention is equally applicable to systems that use laser light energy, radio frequency (RF) energy, microwave energy, or electrical energy converted to heat, as in an ohmic heating coil or contact. Therefore, the following preferred embodiments should not be considered to limit the invention to an ultrasound system.
  • RF radio frequency
  • FIG. 2 illustrates a thermal treatment system 100 in accordance with one embodiment of the invention.
  • Thermal treatment system 100 uses a heat applying element 102 to focus an energy beam 112 on a target mass 104 , which is typically a tumor within a patient 116 .
  • the thermal treatment system 100 is a focused ultrasound system and the heat applying element 102 is a transducer that delivers an ultrasound beam.
  • the transducer 102 may consist of a spherical cap transducer such as that disclosed in the above-incorporated Umemura patent. It will be appreciated by those skilled in the art that a variety of geometric designs for transducer 102 may be employed. Additionally, alternate embodiments of system 100 will use focused radiators, acoustic lenses, or acoustic reflectors in order to achieve optimal focus of beam 112 .
  • Ultrasound is a vibrational energy that is propagated as a mechanical wave through a target medium.
  • transducer 102 generates the mechanical wave by converting an electronic drive signal into mechanical motion.
  • the frequency of the mechanical wave, and therefore ultrasound beam 112 is equal to the frequency of the drive signal.
  • the ultrasound frequency spectrum begins at 20 Khz and typical implementations of system 100 employ frequencies in the range from 0.5 to 10 Mhz.
  • Transducer 102 also converts the electronic drive signal power into acoustic power in ultrasound beam 112 .
  • Ultrasound beam 112 raises the temperature of target mass 104 by transferring this power as heat to target mass 104 .
  • Ultrasound beam 112 is focused on the target mass 104 in order to raise the temperature of the target mass tissue to a point where the tissue is destroyed.
  • the heat distribution within the tissue is controlled by the intensity distribution in the focal spot of beam 112 , the intensity distribution, in turn, is shaped by the interaction of the beam with the tissue and the frequency, duration, and power of beam 112 , which are directly related to the frequency, duration, and power of the electronic drive signal.
  • the transducer 102 focuses beam 112 on a target tissue mass 104 , which is within a patient 116 some distance from skin surface 202 .
  • the distance from skin surface 202 to target mass 104 is the near field 204 , which contains healthy tissue. It is important that tissue in near field 204 is not damaged by beam 112 .
  • Energy zone 206 is the target zone for beam 112 , wherein energy is transferred as heat to the tissue of the target mass 104 .
  • Energy zone 206 is divided into several cross sections of varying depth. Varying the frequency of the electric signal driving transducer 102 can target particular cross sections within energy zone 206 .
  • d is proportional to k 1 (v/f)(R/2a); and (2) l is proportional to k 2 (v/f) (R/2a) 2 .
  • d represents the diameter of the focal spot of beam 112 .
  • R represents the radius of curvature, and 2a represents the diameter, respectively, of transducer 102 . Therefore, the physical parameters associated with transducer 102 are important parameters, as well.
  • l represents the axial length of the focus of beam 112 . Different cross sections can be targeted by changing the frequency f, which will vary the focal length l.
  • v is the speed of sound in body tissue and is approximately 1540 m/s.
  • the same parameters that play an important role in determining the focal length l also play an important role in determining the focal spot diameter d.
  • the focal spot will typically be many times smaller than transducer 102 , the acoustic intensity will be many times higher in the focal spot as compared to the intensity at the transducer. In some implementations, the focal spot intensity can be hundreds or even thousands of times higher than the transducer intensity.
  • the frequency f also effects the intensity distribution within energy zone 206 : The higher the frequency, the tighter the distribution, which is beneficial in terms of not heating near field 204 .
  • the duration of a sonication determines how much heat will actually be transferred to the target mass tissue at the focal spot. For a given signal power and focal spot diameter, a longer duration results in more heat transfer and, therefore, a higher temperature. Thermal conduction and blood flow, however, make the actual temperature distribution within the tissue unpredictable for longer sonication duration. As a result, typical implementations use duration of only a few seconds. In focused ultrasound systems, care must also be taken not to raise the temperature at the focal point too high. A temperature of 100° C. will cause water in the tissue to boil forming gas in the path of beam 112 . The gas blocks the propagation of beam 112 , which significantly impacts the performance of system 100 .
  • Controller 106 controls the mechanical and electrical properties of transducer 102 .
  • controller 106 controls electrical properties such as the frequency, duration, and amplitude of the electronic drive signal and mechanical properties such as the position of transducer 102 .
  • the position of transducer 102 By controlling the position of transducer 102 , the position of the focal spot within target mass 116 can be controlled.
  • controller 106 controls the x-position, z-position, the pitch, and the roll of transducer 102 .
  • a preferred mechanical positioning system for controlling the physical position of the transducer is taught in commonly assigned U.S. patent application Ser. No. 09/628,964, entitled “Mechanical Positioner for MRI Guided Ultrasound Therapy System,” which is hereby incorporated by reference for all it teaches and discloses.
  • electromechanical drives under the control of controller 106 are used to control these positional aspects. It will be apparent to those skilled in the art that other implementations may employ other means to position transducer 102 including hydraulics, gears, motors, servos, etc. Additionally, it must be remembered that controlling the electrical properties, mainly frequency f and phase of transducer 102 controls the position of the focal spot along the y-axis of transducer 102 and the dimensions of the focal volume. Controller 106 uses properties provided by planner 108 to control the mechanical and electrical properties of transducer 102 .
  • Planner 108 automatically constructs a treatment plan, which consists of a series of treatment site represented by thermal dose properties.
  • the purpose of the treatment plan is to ensure complete ablation of target mass 104 by planning a series of sonications that will apply a series of thermal doses at various points within target mass 104 , resulting in a composite thermal dose sufficient to ablate the entire mass.
  • the plan will include the frequency, duration, and power of the sonication and the position and mode of the focal spot for each treatment site in series of treatment sites.
  • the mode of the focal spot refers to the fact that the focal spot can be of varying dimensions. Typically, there will be a range of focal modes from small to large with several intermediate modes in between.
  • the actual size of the focal spot will vary, however, as a function of the focal distance (l), the frequency and focal spot dispersion mode. Therefore, planner 108 must take the mode and focal spot size variation into account when planning the position of the focal spot for a treatment site.
  • the treatment plan is then passed to controller 106 in the relevant format to allow controller 106 to perform its tasks.
  • UI 110 comprises a Graphical User Interface (GUI): A user employs a mouse or touch screen to navigate through menus or choices as displayed on a display device in order to make the appropriate selections and supply the required information.
  • GUI Graphical User Interface
  • imager 114 supplies images of target mass 104 that can be used to determine volume, position, and distance from skin surface 202 .
  • imager 114 is a Magnetic Resonance Imaging (MRI) device and, in one implementation, the images provided are three-dimensional images of target mass 104 .
  • planner 108 receives the input from UI 110 and the images from imager 114 , planner 108 automatically constructs the treatment plan.
  • MRI Magnetic Resonance Imaging
  • the goal of the treatment plan is to completely cover a target tissue mass 300 with a series of sonications 304 so that the entire target mass is fully ablated.
  • a user may, if required, edit the plan by using UI 110 .
  • planner 108 will also produce a predicted thermal dose distribution. This distribution is similar to the distribution illustrated in FIG. 4 , wherein the predicted thermal doses 304 are mapped onto images of target mass 104 provided by imager 114 . In one implementation, the distribution is a three-dimensional distribution. Additionally an algorithm is included in planner 108 that limits the peak temperature of the focal zone so as to prevent evaporation. The algorithm is referred to as the dose predictor.
  • the treatment plan is a three-dimensional treatment plan.
  • FIG. 5 illustrates one preferred process flow diagram for constructing a three-dimensional treatment plan, using three-dimensional images of target mass 104 and a three-dimensional predicted thermal dose distribution 300 .
  • the ability of focusing at different focal lengths (l) leads to variable focal spots and variable lesion sizes in target mass 104 as a function of (y), the transducer axis. Therefore, as a result of the process illustrated in FIG. 5 , planner 108 finds a minimum number of overlapping cross-sectional treatment layers required to ablate a portion of target mass 104 extending from y near to y far .
  • Planner 108 will also predict the lesion size in the cross-sectional layer and will provide the maximal allowed energy in each layer, taking into account the maximum allowed temperature rise.
  • the energy or power will be normalized among different layers, such that the maximal temperature at the focus remains approximately constant throughout the treatment zone 206 .
  • Constructing the three-dimensional treatment plan begins in step 402 with obtaining diagnostic quality images of the target mass.
  • the diagnostic quality images may be the preliminary images supplied by an imager such as imager 114 .
  • planner 108 uses the diagnostic images to define the treatment region.
  • Line (y) will be the axis along which the treatment layers will be defined.
  • planner 108 will perform a dose prediction in step 408 using the maximal power required for small and large spot sizes at (y far ).
  • planner 108 determines if the resulting maximal temperature exceeds the allowed limit. It should be noted that properties such as the maximal power and the maximal temperature limit may be supplied as default thermal dose prediction properties or may be supplied as user supplied thermal dose prediction properties. If the resulting maximal temperature does exceed the allowable limit, the power is scaled down linearly in step 412 until the temperature elevation is within the allowable limit.
  • the small and large focal modes may correspond to modes 0 and 4 , respectively, with additional modes 1 , 2 and 3 falling between modes 0 and 4 . Therefore, in step 414 , planner 108 predicts the maximal power for the intermediate modes 1 , 2 and 3 , from the scaled max powers at modes 0 and 4 . Thus, in step 416 , if there are further modes, planner 108 reverts to step 408 and predicts the maximal power for these modes. If it is the last mode for (y far ) then planner 108 uses the same scaled max power, as in step 418 , to find the corresponding maximal powers for each focal mode at (y near ).
  • planner 108 finds the maximal temperature elevation and lesion size for the appropriate mode and the required maximal power at a point (y l ), such that y near ⁇ y l ⁇ y far .
  • (y l ) is close to (y near ).
  • y l y near +25 mm. If the temperature elevation at (y l ) exceeds the allowable limit as determined in step 422 , then in step 424 the power is scaled down until the temperature elevation is within the limit, and then planner 108 determines the resulting lesion size at (y l ).
  • the first treatment is placed.
  • the treatment will actually be a three-dimensional layer or slice.
  • an auxiliary treatment slice is placed on top of the previous treatment layer using the same height for the second slice as for the first slice.
  • planner 108 determines if more layers are needed to reach (y far ). If more layers are needed, then the process reverts to step 418 , and (y l ) replaces (y near ) (step 432 ) in the algorithm.
  • planner 108 will determine if the layer extends beyond the target limit (y far ). If the layer does extend too far, then the overlap criterion should be used with the outer limit (y far ) as a boundary instead of the previous layer. Using (y far ) in the overlap criterion may cause overdose but will not damage healthy tissue outside target mass 104 .
  • the thermal dose properties are automatically optimized using physiological parameters as the optimization criterion in one implementation mechanical tissue parameters like compressibility, stiffens and scatter are used.
  • a thermal treatment system 500 similar to system 100 of FIG. 2 , includes an online feedback imager 502 .
  • the actual thermal dose delivered with a particular sonication is not the same as the thermal dose predicted by planner 108 .
  • absorption coefficient blood flow, uneven heat conduction, different rates of conduction for different tissue masses, tissue induced beam aberration and variances in system tolerances make it difficult to accurately predict thermal dosages.
  • the actual focal spot dimensions are variable as a function of focal distance (l) and of focal spot dispersion, making accurate thermal dosing predictions even more difficult.
  • the actual thermal dose 606 will often not ablate the predicted amount of tissue.
  • two situations can occur.
  • actual thermal dose 606 may be larger than predicted thermal dose 608 .
  • the second situation is illustrated by comparison 604 in FIG. 7B .
  • actual thermal dose 606 is smaller than predicted thermal dose 608 . Therefore, there is an area 612 of non-ablated tissue remaining after sonication.
  • the online feedback imager 502 provides real-time temperature sensitive magnetic resonance images of target mass 104 after some or all of the sonications.
  • the planner 108 uses the images from the feedback imager 502 to construct an actual thermal dose distribution 600 comparing the actual composite thermal dose to the predicted composite thermal dose as illustrated in FIG. 8 .
  • thermal dose distribution 600 illustrates a comparison of the actual versus predicted thermal dose for each or some of the sonications. As can be seen, overlapping areas 610 and non-ablated areas 612 will result in over- or under-dosing as the treatment plan is implemented and thermal doses are applied to different treatment sites 614 within target mass 104 .
  • the images provided by feedback imager 502 and the updated thermal dose distributions 600 represent three-dimensional data.
  • Planner 108 uses thermal dose distribution 600 to automatically adjust the treatment plan, in real-time, after each sonication or uses the thermal dose distribution 600 in some of the points to adjust for the neighboring points.
  • Planner 108 can adjust the treatment plan by adding treatment sites, removing treatment sites, or continuing to the next treatment site. Additionally, the thermal dose properties of some or all remaining treatment sites may automatically be adjusted by planner 108 based on real-time feedback from feedback imager 502 .
  • planner 108 reformulates the treatment plan automatically after each thermal dose or after some of the sonication points, thus ensuring that target mass 104 is completely ablated in an efficient and effective manner.
  • the feedback provided by online feedback imager 502 might be used to manually adjust the treatment plan or to override the changes made by planner 108 .
  • imager 114 also functions as feedback imager 502 .
  • FIG. 9 A preferred method of controlling thermal dosing in a thermal treatment system (e.g., systems 100 and 500 ) is illustrated in FIG. 9 .
  • a user selects an appropriate clinical application protocol in step 702 .
  • a user may use an interface such as UI 110 to select the clinical application protocol.
  • selecting the clinical application protocol controls a set of default thermal dose prediction parameters.
  • relevant magnetic resonant images of a target mass are retrieved in step 704 .
  • the images may be retrieved by a means such as imager 114 .
  • the images are used to define a target region such as a treatment slice as discussed previously.
  • defining the target region involves manually or automatically tracing the target mass onto the images retrieved in step 704 .
  • the target mass is traced in three dimensions onto three-dimensional images for three-dimensional treatment planning.
  • the operator is allowed to account for obstacles such as bones, gas, or other sensitive tissue and plan accordingly to ensure that the ultrasound beam will not pass through these obstacles. Based on this planning, a patient may be repositioned or the transducer may be repositioned and/or tilted in order to avoid the obstacles.
  • the treatment plan may, for example, be automatically constructed by a planning means such as planner 108 .
  • automatically constructing the treatment plan includes constructing an expected thermal dose distribution showing the predicted thermal dose at each treatment site. This thermal dose distribution may represent a three-dimensional distribution, and, in such an implementation, constructing the treatment plan may follow the steps illustrated in FIG. 5 , and described above.
  • constructing the treatment plan further comprises calculating limits for the ultrasonic energy associated with each sonication so as to prevent evaporation.
  • the treatment plan is edited by manual input.
  • UI 110 may be used to edit the treatment plan.
  • editing the plan may include adding treatment sites, deleting treatment sites, changing the location of some or all of the treatment sites, changing other thermal dose properties for some or all treatment sites, or reconstructing the entire plan.
  • step 720 if the plan is edited, then the process reverts to step 708 and continues from there.
  • verification step 714 is performed. Verification is required to ensure that treatment system 100 is properly registered with regard to the position of the focal spot relative to patient 116 and target mass 104 .
  • verification comprises performing a low energy thermal dose at a predefined spot within said target mass in order to verify proper registration.
  • step 722 the verification could be repeated at full energy level to calibrate the dosing parameters.
  • re-verification may be required depending on the result of step 714 . In this case, the process reverts back to step 714 and verification is performed again.
  • mechanical properties, such as position, relating to transducer 102 may need to be changed (step 720 ) and, therefore, the process reverts to step 708 .
  • the treatment plan is implemented in step 716 .
  • this step comprises capturing temperature sensitive image sequences of the target mass as each step of the plan is being implemented. These images will illustrate the actual thermal dose distribution resulting from each successive thermal dose.
  • An online feedback imager 502 may, for example, provide the temperature sensitive images that are used to construct the actual thermal dose distribution.
  • the actual thermal dose distribution is compared with the predicted thermal dose distribution in order to determine how closely the actual treatments are tracking the treatment plan.
  • the changes may be accomplished manually or automatically and may comprise adding treatment sites, deleting treatment sites, repeating treatment sites, or modifying specific thermal dose properties for some or all of the treatment sites.
  • each thermal dose there may be regions within the target layer that are not covered by accumulated dose contours. These untreated areas are separated into individual regions. Each of these regions is then sent through the process, beginning with step 708 , resulting in an updated treatment plan constructed to treat the remaining regions. The process will repeat until there are no more untreated regions.
  • each treatment region may be maintained as a two-dimensional linked list of pixel ranges sorted by (y) and then (x) coordinates as illustrated in FIGS. 10A-C .
  • the treatment region is a continuous region 802 represented by the lighter pixels.
  • the pixel distribution is then represented by the data structure 804 .
  • This type of representation is called “run-length encoding.”
  • the data structure 804 contains linked lists 806 by row indicating the pixels that contain treatment region 802 .
  • list element 806 a indicates that the pixel range from 1 to 2 contains a portion of treatment region 802
  • 806 b indicates that the pixel range from 7 to 7 contains a portion of treatment region 802
  • 806 c indicates that the pixel range from 11 to 11 contains a portion of treatment region 802 . It can also be seen that rows 0 and 5 do not contain any portion of treatment region 802 ; therefore, these rows in data structure 804 do not contain any pixel ranges.
  • the area of the target mass that is destroyed (the treated region) is represented in the same fashion as the untreated region shown in FIG. 10A .
  • the treated region ( FIG. 10B ) is subtracted from the untreated region in order to define the remaining untreated region within treatment region 802 .
  • These areas can then be sent back to the planning stage (step 720 ) and the treatment plan can be updated.
  • the subtraction, therefore, of two regions involves traversing the lines in each region and subtracting a line in the first data structure from its corresponding line in the second data structure.
  • each segment 806 d and 806 e in row 1 of data structure 810 is subtracted from each segment 806 a, 806 b, and 806 c in row 1 of data structure 804 .
  • segment 806 d is subtracted from segment 806 a using Rule (2).
  • Rule (2) results in a run-length segment that contains no pixels, i.e., a range of 0.
  • segment 806 d is the same as segment 806 a and that subtraction of the two should result in 0, as it does under Rule (2).
  • segment 806 d is subtracted from segment 806 b, using Rule (1).
  • the pixel range described by segment 806 d does not overlap the range described by segment 806 b, subtracting 806 d from 806 b should have no effect. Indeed, application of rule (1) has no effect on segment 806 b.
  • segment 806 e must be subtracted from segment 806 b. As can be seen, segment 806 e overlaps segment 806 b entirely. Therefore, application of rule (2), which is the appropriate rule for these two segments, results in 0. In other words, if region 802 is a target mass, and region 808 defines an expected thermal dose, then the dose represented by segment 806 e will completely ablate the portion of the target mass represented by segment 806 b. The same result occurs for the subtraction of segments 806 e and 806 d from segment 806 c. The subtraction then continues for each row as illustrated by steps 2, 3, and 4 above. The resulting region is illustrated in FIG.
  • regions 812 , 814 , 816 , and 818 are represented by data structure 820 and associated linked lists of run-length segments 806 . It is these untreated regions 812 , 814 , 816 , and 818 that will require the treatment plan to be updated by returning to the planning stage in step 720 .
  • An alternative method for updating the treatment plan involves eliminating steps 710 and 712 in FIG. 9 .
  • the system accepts a target mass 914 to be treated and follows the steps illustrated in FIG. 11 .
  • step 902 it is determined if there is an untreated region 914 . If there is, then treatment site 916 is selected in step 904 , and thermal dose properties are estimated so as to deliver the appropriate thermal dose the treatment site 916 .
  • step 906 the thermal dose is applied to treatment site 916 resulting in a treated region 918 .
  • the size of treated region is calculated and stored as a linked-list so that in step 910 the treated region can be subtracted from the untreated region 920 in order to determine the remaining untreated region.
  • the process then reverts to step 902 , and a new treatment site is selected. Once the entire target mass 914 is treated, there will not be any untreated regions and the process will exit.
  • step 726 it is determined in step 726 whether to restart a treatment or to exit. Additionally, if there is insufficient information or a fatal error occurs in any of steps 704 - 716 , the process will automatically go to step 726 , where it can be decide to proceed with a new treatment plan or to exit altogether.
  • the invention provides methods for constructing a three-dimensional thermal dose treatment plan, including:

Abstract

A thermal treatment system including a heat applying element for generating thermal doses for ablating a target mass in a patient, a controller for controlling thermal dose properties of the heat applying element, an imager for providing preliminary images of the target mass and thermal images during the treatment, and a planner for automatically constructing a treatment plan, comprising a series of treatment sites that are each represented by a set of thermal dose properties. The planner automatically constructs the treatment plan based on input information including one or more of a volume of the target mass, a distance from a skin surface of the patient to the target mass, a set of default thermal dose prediction properties, a set of user specified thermal dose prediction properties, physical properties of the heat applying elements, and images provided by the imager. The default thermal dose prediction properties are preferably based on a type of clinical application and include at least one of thermal dose threshold, thermal dose prediction algorithm, maximum allowed energy for each thermal dose, thermal dose duration for each treatment site, cooling time between thermal doses, and electrical properties for the heat applying element. The user specified thermal dose prediction properties preferably include at least one or more of overrides for any default thermal dose prediction properties, treatment site grid density; and thermal dose prediction properties not specified as default thermal dose prediction properties from the group comprised of thermal dose threshold, thermal dose prediction algorithm, maximum allowed energy for each thermal dose, thermal dose duration for each treatment site cooling time between thermal doses, and electrical properties for the heat applying element.

Description

CROSS-REFERENCE TO RELATED APPLICATION
This application is a reissue of U.S. patent application Ser. No. 09/724,670, filed Nov. 28, 2000, issued as U.S. Pat. No. 6,618,620.
FIELD OF INVENTION
The present invention relates generally to thermal treatment systems, and more particularly to a method and apparatus for controlling thermal dosing in a thermal treatment system.
BACKGROUND
Thermal energy, such as generated by high intensity focused ultrasonic waves (acoustic waves with a frequency greater than about 20 kilohertz), may be used to therapeutically treat internal tissue regions within a patient. For example, ultrasonic waves may be used to ablate tumors, thereby obviating the need for invasive surgery. For this purpose, piezoelectric transducers driven by electric signals to produce ultrasonic energy have been suggested that may be placed external to the patient but in close proximity to the tissue to be ablated. The transducer is geometrically shaped and positioned such that the ultrasonic energy is focused at a “focal zone” corresponding to a target tissue region within the patient, heating the target tissue region until the tissue is coagulated. The transducer may be sequentially focused and activated at a number of focal zones in close proximity to one another. This series of “sonications” is used to cause coagulation necrosis of an entire tissue structure, such as a tumor, of a desired size and shape.
In such focused ultrasound systems, the transducer is preferably geometrically shaped and positioned so that the ultrasonic energy is focused at a “focal zone” corresponding to the target tissue region, heating the region until the tissue is necrosed. The transducer may be sequentially focused and activated at a number of focal zones in close proximity to one another. For example, this series of “sonications” may be used to cause coagulation necrosis of an entire tissue structure, such as a tumor, of a desired size and shape.
By way of illustration, FIG. 1A depicts a phased array transducer 10 having a “spherical cap” shape. The transducer 10 includes a plurality of concentric rings 12 disposed on a curved surface having a radius of curvature defining a portion of a sphere. The concentric rings 12 generally have equal surface areas and may also be divided circumferentially 14 into a plurality of curved transducer sectors, or elements 16, creating a “tiling” of the face of the transducer 10. The transducer elements 16 are constructed of a piezoelectric material such that, upon being driven with a sinus wave near the resonant frequency of the piezoelectric material, the elements 16 vibrate according to the phase and amplitude of the exciting sinus wave, thereby creating the desired ultrasonic wave energy.
As illustrated in FIG. 1B, the phase shift and amplitude of the respective sinus “drive signal” for each transducer element 16 is individually controlled so as to sum the emitted ultrasonic wave energy 18 at a focal zone 20 having a desired mode of focused planar and volumetric pattern. This is accomplished by coordinating the signal phase of the respective transducer elements 16 in such a manner that they constructively interfere at specific locations, and destructively cancel at other locations. For example, if each of the elements 16 are driven with drive signals that are in phase with one another, (known as “mode 0”), the emitted ultrasonic wave energy 18 are focused at a relatively narrow focal zone. Alternatively, the elements 16 may be driven with respective drive signals that are in a predetermined shifted-phase relationship with one another (referred to in U.S. Pat. No. 4,865,042 to Umemura et al. as “mode n”). This results in a focal zone that includes a plurality of 2n zones disposed about an annulus, i.e., generally defining an annular shape, creating a wider focus that causes necrosis of a larger tissue region within a focal plane intersecting the focal zone. Multiple shapes of the focal spot can be created by controlling the relative phases and amplitudes of the emmitted energy from the array, including steering and scanning of the beam, enabling electronic control of the focused beam to cover and treat multiple of spots in the defined zone of a defined tumor inside the body.
More advanced techniques for obtaining specific focal distances and shapes are disclosed in U.S. patent application Ser. No. 09/626,176, filed Jul. 27, 2000, entitled “Systems and Methods for Controlling Distribution of Acoustic Energy Around a Focal Point Using a Focused Ultrasound System;” U.S. patent application Ser. No. 09/556,095, filed Apr. 21, 2000, entitled “Systems and Methods for Reducing Secondary Hot Spots in a Phased Array Focused Ultrasound System;” and U.S. patent application Ser. No. 09/557,078, filed Apr. 21, 2000, entitled “Systems and Methods for Creating Longer Necrosed Volumes Using a Phased Array Focused Ultrasound System.” The foregoing (commonly assigned) patent applications, along with U.S. Pat. No. 4,865,042, are all hereby incorporated by reference for all they teach and disclose.
It is significant to implementing these focal positioning and shaping techniques to provide a transducer control system that allows the phase of each transducer element to be independently controlled. To provide for precise positioning and dynamic movement and reshaping of the focal zone, it is desirable to be able to alter the phase and/or amplitude of the individual elements relatively fast, e.g., in the μ second range, to allow switching between focal points or modes of operation. As taught in the above-incorporated U.S. patent application Ser. No. 09/556,095, it is also desirable to be able to rapidly change the drive signal frequency of one or more elements.
Further, in a MRI-guided focused ultrasound system, it is desirable to be able to drive the ultrasound transducer array without creating electrical harmonics, noise, or fields that interfere with the ultra-sensitive receiver signals that create the images. A system for individually controlling and dynamically changing the phase and amplitude of each transducer element drive signal in phased array focused ultrasound transducer in a manner which does not interfere with the imaging system is taught in commonly assigned U.S. patent application Ser. No. [not-yet-assigned; Lyon & Lyon Attorney Docket No. 254/189, entitled “Systems and Methods for Controlling a Phased Array Focussed Ultrasound System,”], which was filed on the same date herewith and which is hereby incorporated by reference for all it teaches and discloses.
Notably, after the delivery of a thermal dose, e.g., ultrasound sonication, a cooling period is required to avoid harmful and painful heat build up in healthy tissue adjacent a target tissue structure. This cooling period may be significantly longer than the thermal dosing period. Since a large number of sonications may be required in order to fully ablate the target tissue site, the overall time required can be significant. If the procedure is MRI-guided, this means that the patient must remain motionless in a MRI machine for a significant period of time, which can be very stressful. At the same time, it may be critical that the entire target tissue structure be ablated (such as, e.g., in the case of a malignant cancer tumor), and that the procedure not take any short cuts just in the name of patient comfort.
Accordingly, it would be desirable to provide systems and methods for treating a tissue region using thermal energy, such as focused ultrasound energy, wherein the thermal dosing is applied in a more efficient and effective manner.
SUMMARY OF THE INVENTION
In accordance with a first aspect of the invention, a thermal treatment system is provided, the system including a heat applying element for generating a thermal dose used to ablate a target mass in a patient, a controller for controlling thermal dose properties of the heat applying element, an imager for providing preliminary images of the target mass and thermal images during the treatment, and a planner for automatically constructing a treatment plan, comprising a series of treatment sites that are each represented by a set of thermal dose properties. By way of non-limiting example only, the heat applying element may apply any of ultrasound energy, laser light energy, radio frequency (RF) energy, microwave energy, or electrical energy.
In a preferred embodiment, the planner automatically constructs the treatment plan based on input information including one or more of a volume of the target mass, a distance from a skin surface of the patient to the target mass, a set of default thermal dose prediction properties, a set of user specified thermal dose prediction properties, physical properties of the heat applying elements, and images provided by the imager. The default thermal dose prediction properties are preferably based on a type of clinical application and include at least one of thermal dose threshold, thermal dose prediction algorithm, maximum allowed energy for each thermal dose, thermal dose duration for each treatment site, cooling time between thermal doses, and electrical properties for the heat applying element. The user specified thermal dose prediction properties preferably include at least one or more of overrides for any default thermal dose prediction properties, treatment site grid density; and thermal dose prediction properties not specified as default thermal dose prediction properties from the group comprised of thermal dose threshold, thermal dose prediction algorithm, maximum allowed energy for each thermal dose, thermal dose duration for each treatment site cooling time between thermal doses, and electrical properties for the heat applying element.
Preferably, the treatment plan ensures that the entire target mass is covered by a series of thermal doses so as to obtain a composite thermal dose sufficient to ablate the entire target mass, and the thermal dose properties are automatically optimized using physiological properties as the optimization criterion. Preferably, the planner limits the thermal dose at each treatment site in order to prevent evaporation or carbonization.
In a preferred embodiment, the planner constructs a predicted thermal dose distribution in three dimensions, illustrating the predicted thermal dose threshold contours of each treatment site in the treatment plan. A User Interface (UI) may also be provided for entering user specified thermal dose prediction properties and for editing the treatment plan once the treatment plan is constructed. A feedback imager for providing thermal images may also be provided, wherein the thermal images illustrate the actual thermal dose distribution resulting at each treatment site. In one embodiment, the imager acts as the feedback imager.
In accordance with another aspect of the invention, a focused ultrasound system is provided, including a transducer for generating ultrasound energy that results in thermal doses used to ablate a target mass in a patient, a controller for controlling thermal dose properties of the transducer, an imager for providing preliminary images of the target, and for providing thermal images illustrating an actual thermal dose distribution in the patient, and a planner for automatically constructing a treatment plan using the preliminary images, the treatment plan comprising a series of treatment sites represented by a set of thermal dose properties used by the controller to control the transducer.
The planner preferably constructs a predicted thermal dose distribution illustrating the predicted thermal dose contours of each treatment site in the treatment plan, wherein after a thermal dose is delivered to a treatment site in the treatment plan, the actual thermal dose distribution is compared to the predicted thermal dose distribution to determine remaining untreated locations within the target mass. The planner preferably automatically evaluates the treatment plan based on the remaining untreated locations and will update the treatment plan to ensure complete ablation of the target mass is achieved by adding treatment sites, removing treatment sites, modifying existing treatment sites, or leaving the treatment plan unchanged. In some embodiments, a user can manually adjust the treatment plan based on the remaining untreated locations.
Preferably, the imager provides outlines of sensitive regions within the patient where ultrasonic waves are not allowed to pass, wherein the processor uses the outlines in constructing the treatment plan so as to avoid exposing the sensitive regions to ultrasound.
In accordance with still another aspect of the invention, a method of controlling thermal dosing in a thermal treatment system is provided, which includes selecting an appropriate clinical application protocol, the selected application protocol having associated with it certain default thermal dosing properties; retrieving relevant magnetic resonant images for thermal dose planning; tracing a target mass on the images; entering user specified thermal dosing properties and selectively modifying the default thermal dosing properties; and automatically constructing a treatment plan representing thermal doses to be applied to treatment sites, the treatment plan based on the default thermal dosing properties and the user specified thermal dosing properties.
In preferred implementations, tracing the target mass can be done manually or automatically, and may include evaluating the target mass to ensure that obstacles including bones, gas, or other sensitive tissue will not interfere with the thermal doses and repositioning a patient or a heat applying element in order to bypass any such obstacles. Preferably, the treatment plan ensures that a target mass receives a composite thermal dose sufficient to ablate the target mass, wherein automatically constructing the treatment plan includes predicting and displaying a predicted thermal dose distribution. Preferably, automatically constructing the treatment plan further includes calculating limits for each thermal dose to be applied to each treatment site in order to prevent evaporation or carbonation.
In a preferred implementation, the treatment plan may be manually edited, including at least one of adding treatment sites, deleting treatment sites, changing the location of treatment sites, changing thermal dosing properties, and reconstructing the entire treatment plan with new thermal dosing properties.
In one implementation, the method includes applying a low energy thermal dose at a predetermined spot within the target mass in order to verify proper registration, and evaluating said predetermined spot and adjusting and/or re-verifying if necessary. In a following step, the low energy thermal dose could be extended to a full dose sonication that will be evaluated to assess the thermal dosing parameters as a scaling factor for the full treatment.
Other aspects and features of the invention will become apparent hereinafter.
BRIEF DESCRIPTION OF THE DRAWINGS
The drawings illustrate both the design and utility of preferred embodiments of the invention, in which similar elements in different embodiments are referred to by the same reference numbers for purposes of ease in illustration, and wherein:
FIG. 1A is a top view of an exemplary spherical cap transducer comprising a plurality of transducer elements to be driven in a phased array as part of a focussed ultrasound system.
FIG. 1B is a partially cut-away side view of the transducer of FIG. 1A, illustrating the concentrated emission of focused ultrasonic energy in a targeted focal region.
FIG. 2 is simplified schematic block diagram of a thermal treatment system for providing thermal energy dosing of a target tissue region in a patient.
FIG. 3 is a cross-sectional view of an ultrasonic transducer and target tissue mass to be treated in a preferred embodiment of the system of FIG. 2.
FIG. 4 is a cross-sectional view of a target tissue mass, illustrating a series of planned sonication areas.
FIG. 5 is a preferred process flow diagram for constructing a three-dimensional treatment plan using the system of FIG. 2.
FIG. 6 is a simplified schematic block diagram of an alternate thermal treatment system comprising a feedback image generator.
FIGS. 7A and 7B are two-dimensional representations of a target sonication areas, illustrating instances in which the actual thermal ablation is either greater than (FIG. 7A), or less than (FIG. 7B), the predicted amount.
FIG. 8 illustrates a comparison of actual versus predicted thermal doses for an entire target tissue region constructed by the system of FIG. 6 using images from the feedback image generator.
FIG. 9 illustrates a preferred method of controlling thermal dosing in a thermal treatment system.
FIG. 10A illustrates a two dimensional pixel representation of a predicted thermal dose to be applied to a target tissue region.
FIG. 10B illustrates a two dimensional pixel representation of an actual thermal dose resulting from a thermal treatment intended to result in the predicted thermal dose of FIG. 10A.
FIG. 10C illustrates a two dimensional pixel representation of a remaining untreated target tissue region derived by subtracting the pixel representation of FIG. 10B from the pixel representation of FIG. 10A.
FIG. 11 illustrates a preferred method for updating a thermal treatment plan.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The invention will now be illustrated by examples that use an ultrasound transducer as the means of delivering energy to a target mass. It will be apparent to those skilled in the art, however, that other energy delivery vehicles can be used. For example, the invention is equally applicable to systems that use laser light energy, radio frequency (RF) energy, microwave energy, or electrical energy converted to heat, as in an ohmic heating coil or contact. Therefore, the following preferred embodiments should not be considered to limit the invention to an ultrasound system.
FIG. 2 illustrates a thermal treatment system 100 in accordance with one embodiment of the invention. Thermal treatment system 100 uses a heat applying element 102 to focus an energy beam 112 on a target mass 104, which is typically a tumor within a patient 116. In one preferred implementation, the thermal treatment system 100 is a focused ultrasound system and the heat applying element 102 is a transducer that delivers an ultrasound beam. In this embodiment, the transducer 102 may consist of a spherical cap transducer such as that disclosed in the above-incorporated Umemura patent. It will be appreciated by those skilled in the art that a variety of geometric designs for transducer 102 may be employed. Additionally, alternate embodiments of system 100 will use focused radiators, acoustic lenses, or acoustic reflectors in order to achieve optimal focus of beam 112.
Ultrasound is a vibrational energy that is propagated as a mechanical wave through a target medium. In system 100, transducer 102 generates the mechanical wave by converting an electronic drive signal into mechanical motion. The frequency of the mechanical wave, and therefore ultrasound beam 112, is equal to the frequency of the drive signal. The ultrasound frequency spectrum begins at 20 Khz and typical implementations of system 100 employ frequencies in the range from 0.5 to 10 Mhz. Transducer 102 also converts the electronic drive signal power into acoustic power in ultrasound beam 112. Ultrasound beam 112 raises the temperature of target mass 104 by transferring this power as heat to target mass 104. Ultrasound beam 112 is focused on the target mass 104 in order to raise the temperature of the target mass tissue to a point where the tissue is destroyed. The heat distribution within the tissue is controlled by the intensity distribution in the focal spot of beam 112, the intensity distribution, in turn, is shaped by the interaction of the beam with the tissue and the frequency, duration, and power of beam 112, which are directly related to the frequency, duration, and power of the electronic drive signal.
As seen in FIG. 3, the transducer 102 focuses beam 112 on a target tissue mass 104, which is within a patient 116 some distance from skin surface 202. The distance from skin surface 202 to target mass 104 is the near field 204, which contains healthy tissue. It is important that tissue in near field 204 is not damaged by beam 112. Energy zone 206 is the target zone for beam 112, wherein energy is transferred as heat to the tissue of the target mass 104. Energy zone 206 is divided into several cross sections of varying depth. Varying the frequency of the electric signal driving transducer 102 can target particular cross sections within energy zone 206.
Two proportionalities illustrate this point: (1) d is proportional to k1(v/f)(R/2a); and (2) l is proportional to k2(v/f) (R/2a)2. In (1), d represents the diameter of the focal spot of beam 112. R represents the radius of curvature, and 2a represents the diameter, respectively, of transducer 102. Therefore, the physical parameters associated with transducer 102 are important parameters, as well. In (2), l represents the axial length of the focus of beam 112. Different cross sections can be targeted by changing the frequency f, which will vary the focal length l. In both (1) and (2), v is the speed of sound in body tissue and is approximately 1540 m/s.
As can be seen, the same parameters that play an important role in determining the focal length l, also play an important role in determining the focal spot diameter d. Because the focal spot will typically be many times smaller than transducer 102, the acoustic intensity will be many times higher in the focal spot as compared to the intensity at the transducer. In some implementations, the focal spot intensity can be hundreds or even thousands of times higher than the transducer intensity. The frequency f also effects the intensity distribution within energy zone 206: The higher the frequency, the tighter the distribution, which is beneficial in terms of not heating near field 204.
The duration of a sonication determines how much heat will actually be transferred to the target mass tissue at the focal spot. For a given signal power and focal spot diameter, a longer duration results in more heat transfer and, therefore, a higher temperature. Thermal conduction and blood flow, however, make the actual temperature distribution within the tissue unpredictable for longer sonication duration. As a result, typical implementations use duration of only a few seconds. In focused ultrasound systems, care must also be taken not to raise the temperature at the focal point too high. A temperature of 100° C. will cause water in the tissue to boil forming gas in the path of beam 112. The gas blocks the propagation of beam 112, which significantly impacts the performance of system 100.
Controller 106 controls the mechanical and electrical properties of transducer 102. For example, controller 106 controls electrical properties such as the frequency, duration, and amplitude of the electronic drive signal and mechanical properties such as the position of transducer 102. By controlling the position of transducer 102, the position of the focal spot within target mass 116 can be controlled. In one embodiment, controller 106 controls the x-position, z-position, the pitch, and the roll of transducer 102. A preferred mechanical positioning system for controlling the physical position of the transducer is taught in commonly assigned U.S. patent application Ser. No. 09/628,964, entitled “Mechanical Positioner for MRI Guided Ultrasound Therapy System,” which is hereby incorporated by reference for all it teaches and discloses.
In one implementation, electromechanical drives under the control of controller 106 are used to control these positional aspects. It will be apparent to those skilled in the art that other implementations may employ other means to position transducer 102 including hydraulics, gears, motors, servos, etc. Additionally, it must be remembered that controlling the electrical properties, mainly frequency f and phase of transducer 102 controls the position of the focal spot along the y-axis of transducer 102 and the dimensions of the focal volume. Controller 106 uses properties provided by planner 108 to control the mechanical and electrical properties of transducer 102.
Planner 108 automatically constructs a treatment plan, which consists of a series of treatment site represented by thermal dose properties. The purpose of the treatment plan is to ensure complete ablation of target mass 104 by planning a series of sonications that will apply a series of thermal doses at various points within target mass 104, resulting in a composite thermal dose sufficient to ablate the entire mass.
For example, the plan will include the frequency, duration, and power of the sonication and the position and mode of the focal spot for each treatment site in series of treatment sites. The mode of the focal spot refers to the fact that the focal spot can be of varying dimensions. Typically, there will be a range of focal modes from small to large with several intermediate modes in between. The actual size of the focal spot will vary, however, as a function of the focal distance (l), the frequency and focal spot dispersion mode. Therefore, planner 108 must take the mode and focal spot size variation into account when planning the position of the focal spot for a treatment site. The treatment plan is then passed to controller 106 in the relevant format to allow controller 106 to perform its tasks.
In order to construct the treatment plan, planner 108 uses input from User Interface (UI) 110 and imager 114. For example, in one implementation, a user specifies the clinical application protocol, i.e., breast, pelvis, eye, prostate, etc., via UI 110. Selection of the clinical application protocol may control at least some of the default thermal dose prediction properties such as thermal dose threshold, thermal dose prediction algorithm, maximum allowed energy for each thermal dose, thermal dose duration for each treatment site, cooling time between thermal doses, and electrical properties for the heat applying element.
In other implementations, some or all of these properties are input through UI 110 as user specified thermal dose prediction properties. Other properties that may be input as user specified thermal dose prediction properties are the sonication grid density (how much the sonications should overlap) and the physical parameters of transducer 102. The latter two properties may also be defined as default parameters in certain implementations.
Additionally, a user may edit any of the default parameters via UI 110. In one implementation, UI 110 comprises a Graphical User Interface (GUI): A user employs a mouse or touch screen to navigate through menus or choices as displayed on a display device in order to make the appropriate selections and supply the required information.
To further aid planner 108 in constructing the treatment plan, imager 114 supplies images of target mass 104 that can be used to determine volume, position, and distance from skin surface 202. In a typical implementation, imager 114 is a Magnetic Resonance Imaging (MRI) device and, in one implementation, the images provided are three-dimensional images of target mass 104. Once planner 108 receives the input from UI 110 and the images from imager 114, planner 108 automatically constructs the treatment plan.
As illustrated in FIG. 4, the goal of the treatment plan is to completely cover a target tissue mass 300 with a series of sonications 304 so that the entire target mass is fully ablated. In one implementation, once the treatment plan is constructed a user may, if required, edit the plan by using UI 110. In one implementation, planner 108 will also produce a predicted thermal dose distribution. This distribution is similar to the distribution illustrated in FIG. 4, wherein the predicted thermal doses 304 are mapped onto images of target mass 104 provided by imager 114. In one implementation, the distribution is a three-dimensional distribution. Additionally an algorithm is included in planner 108 that limits the peak temperature of the focal zone so as to prevent evaporation. The algorithm is referred to as the dose predictor.
In one implementation, the treatment plan is a three-dimensional treatment plan. FIG. 5 illustrates one preferred process flow diagram for constructing a three-dimensional treatment plan, using three-dimensional images of target mass 104 and a three-dimensional predicted thermal dose distribution 300. The ability of focusing at different focal lengths (l) leads to variable focal spots and variable lesion sizes in target mass 104 as a function of (y), the transducer axis. Therefore, as a result of the process illustrated in FIG. 5, planner 108 finds a minimum number of overlapping cross-sectional treatment layers required to ablate a portion of target mass 104 extending from ynear to yfar.
Planner 108 will also predict the lesion size in the cross-sectional layer and will provide the maximal allowed energy in each layer, taking into account the maximum allowed temperature rise. The energy or power will be normalized among different layers, such that the maximal temperature at the focus remains approximately constant throughout the treatment zone 206.
Constructing the three-dimensional treatment plan begins in step 402 with obtaining diagnostic quality images of the target mass. For example, the diagnostic quality images may be the preliminary images supplied by an imager such as imager 114. In step 404, planner 108 uses the diagnostic images to define the treatment region. Then, in step 406, a line y=[ynear:yfar] is defined such that (y) cuts through target zone 206 perpendicular to transducer along the transducer axis from the nearest point within target mass 104 (ynear) to the furthest point (yfar). Line (y) will be the axis along which the treatment layers will be defined.
Once (y) is defined planner 108 will perform a dose prediction in step 408 using the maximal power required for small and large spot sizes at (yfar). In step 410, planner 108 determines if the resulting maximal temperature exceeds the allowed limit. It should be noted that properties such as the maximal power and the maximal temperature limit may be supplied as default thermal dose prediction properties or may be supplied as user supplied thermal dose prediction properties. If the resulting maximal temperature does exceed the allowable limit, the power is scaled down linearly in step 412 until the temperature elevation is within the allowable limit.
The small and large focal modes may correspond to modes 0 and 4, respectively, with additional modes 1, 2 and 3 falling between modes 0 and 4. Therefore, in step 414, planner 108 predicts the maximal power for the intermediate modes 1, 2 and 3, from the scaled max powers at modes 0 and 4. Thus, in step 416, if there are further modes, planner 108 reverts to step 408 and predicts the maximal power for these modes. If it is the last mode for (yfar) then planner 108 uses the same scaled max power, as in step 418, to find the corresponding maximal powers for each focal mode at (ynear). Then in step 420, planner 108 finds the maximal temperature elevation and lesion size for the appropriate mode and the required maximal power at a point (yl), such that ynear<yl<yfar. Preferably, (yl) is close to (ynear). For example, in one implementation, yl=ynear+25 mm. If the temperature elevation at (yl) exceeds the allowable limit as determined in step 422, then in step 424 the power is scaled down until the temperature elevation is within the limit, and then planner 108 determines the resulting lesion size at (yl).
Using an overlap criterion with respect to the (ynear) boundary, which may be provided via a sonication grid density, the first treatment is placed. The treatment will actually be a three-dimensional layer or slice. Then, in step 428, using an inter-layer overlap criterion, an auxiliary treatment slice is placed on top of the previous treatment layer using the same height for the second slice as for the first slice. In step 430, planner 108 determines if more layers are needed to reach (yfar). If more layers are needed, then the process reverts to step 418, and (yl) replaces (ynear) (step 432) in the algorithm.
Once the last treatment layer is reached, planner 108 will determine if the layer extends beyond the target limit (yfar). If the layer does extend too far, then the overlap criterion should be used with the outer limit (yfar) as a boundary instead of the previous layer. Using (yfar) in the overlap criterion may cause overdose but will not damage healthy tissue outside target mass 104.
In one implementation, the thermal dose properties are automatically optimized using physiological parameters as the optimization criterion in one implementation mechanical tissue parameters like compressibility, stiffens and scatter are used.
Referring to FIG. 6, a thermal treatment system 500, similar to system 100 of FIG. 2, includes an online feedback imager 502. In practice, the actual thermal dose delivered with a particular sonication is not the same as the thermal dose predicted by planner 108. As mentioned previously, absorption coefficient blood flow, uneven heat conduction, different rates of conduction for different tissue masses, tissue induced beam aberration and variances in system tolerances make it difficult to accurately predict thermal dosages. Moreover, the actual focal spot dimensions are variable as a function of focal distance (l) and of focal spot dispersion, making accurate thermal dosing predictions even more difficult.
As illustrated in FIGS. 7A-B, the actual thermal dose 606 will often not ablate the predicted amount of tissue. In particular, two situations can occur. First, as illustrated by comparison 602 in FIG. 7A, actual thermal dose 606 may be larger than predicted thermal dose 608. In this case there will be an overlap of ablated tissue 610. The second situation is illustrated by comparison 604 in FIG. 7B. In this case, actual thermal dose 606 is smaller than predicted thermal dose 608. Therefore, there is an area 612 of non-ablated tissue remaining after sonication.
The online feedback imager 502 provides real-time temperature sensitive magnetic resonance images of target mass 104 after some or all of the sonications. The planner 108 uses the images from the feedback imager 502 to construct an actual thermal dose distribution 600 comparing the actual composite thermal dose to the predicted composite thermal dose as illustrated in FIG. 8. In particular, thermal dose distribution 600 illustrates a comparison of the actual versus predicted thermal dose for each or some of the sonications. As can be seen, overlapping areas 610 and non-ablated areas 612 will result in over- or under-dosing as the treatment plan is implemented and thermal doses are applied to different treatment sites 614 within target mass 104.
In one implementation, the images provided by feedback imager 502 and the updated thermal dose distributions 600 represent three-dimensional data. Planner 108 uses thermal dose distribution 600 to automatically adjust the treatment plan, in real-time, after each sonication or uses the thermal dose distribution 600 in some of the points to adjust for the neighboring points. Planner 108 can adjust the treatment plan by adding treatment sites, removing treatment sites, or continuing to the next treatment site. Additionally, the thermal dose properties of some or all remaining treatment sites may automatically be adjusted by planner 108 based on real-time feedback from feedback imager 502.
As mentioned, planner 108 reformulates the treatment plan automatically after each thermal dose or after some of the sonication points, thus ensuring that target mass 104 is completely ablated in an efficient and effective manner. In addition, the feedback provided by online feedback imager 502 might be used to manually adjust the treatment plan or to override the changes made by planner 108. It should be noted that in one example embodiment, imager 114 also functions as feedback imager 502.
A preferred method of controlling thermal dosing in a thermal treatment system (e.g., systems 100 and 500) is illustrated in FIG. 9. Initially, a user selects an appropriate clinical application protocol in step 702. For example, a user may use an interface such as UI 110 to select the clinical application protocol. In one embodiment, selecting the clinical application protocol controls a set of default thermal dose prediction parameters. After the clinical application is selected, relevant magnetic resonant images of a target mass are retrieved in step 704. For example, the images may be retrieved by a means such as imager 114. In step 706, the images are used to define a target region such as a treatment slice as discussed previously. In one embodiment, defining the target region involves manually or automatically tracing the target mass onto the images retrieved in step 704. In one implementation, the target mass is traced in three dimensions onto three-dimensional images for three-dimensional treatment planning. In another embodiment that uses ultrasound, the operator is allowed to account for obstacles such as bones, gas, or other sensitive tissue and plan accordingly to ensure that the ultrasound beam will not pass through these obstacles. Based on this planning, a patient may be repositioned or the transducer may be repositioned and/or tilted in order to avoid the obstacles.
In step 708, the user may enter additional thermal dose prediction properties or modify any default thermal dose prediction properties already selected. For example, these additional properties may be entered via UI 110. Then in step 710, a treatment plan is automatically constructed based on the properties obtained in the previous steps. The purpose of the treatment plan is to ensure a proper composite thermal dose sufficient to ablate the target mass by applying a series of thermal doses to a series of treatment sites, automatically accounting for variations in the focal spot sizes and in the thermal dose actually delivered to the treatment site.
The treatment plan may, for example, be automatically constructed by a planning means such as planner 108. In one embodiment, automatically constructing the treatment plan includes constructing an expected thermal dose distribution showing the predicted thermal dose at each treatment site. This thermal dose distribution may represent a three-dimensional distribution, and, in such an implementation, constructing the treatment plan may follow the steps illustrated in FIG. 5, and described above. In another embodiment, constructing the treatment plan further comprises calculating limits for the ultrasonic energy associated with each sonication so as to prevent evaporation.
In step 712, the treatment plan is edited by manual input. For example, UI 110 may be used to edit the treatment plan. In one embodiment, editing the plan may include adding treatment sites, deleting treatment sites, changing the location of some or all of the treatment sites, changing other thermal dose properties for some or all treatment sites, or reconstructing the entire plan. As illustrated by step 720, if the plan is edited, then the process reverts to step 708 and continues from there. Once the plan is set, then verification step 714 is performed. Verification is required to ensure that treatment system 100 is properly registered with regard to the position of the focal spot relative to patient 116 and target mass 104. In one embodiment, verification comprises performing a low energy thermal dose at a predefined spot within said target mass in order to verify proper registration. In a following step, the verification could be repeated at full energy level to calibrate the dosing parameters. As illustrated by step 722, re-verification may be required depending on the result of step 714. In this case, the process reverts back to step 714 and verification is performed again. On the other hand, mechanical properties, such as position, relating to transducer 102 may need to be changed (step 720) and, therefore, the process reverts to step 708.
Once the verification is complete, the treatment plan is implemented in step 716. In one embodiment, this step comprises capturing temperature sensitive image sequences of the target mass as each step of the plan is being implemented. These images will illustrate the actual thermal dose distribution resulting from each successive thermal dose. An online feedback imager 502 may, for example, provide the temperature sensitive images that are used to construct the actual thermal dose distribution. In step 718, the actual thermal dose distribution is compared with the predicted thermal dose distribution in order to determine how closely the actual treatments are tracking the treatment plan. Then in step 724, it is determined if the treatment can proceed to the next step (repeat step 716), or if changes must be made to the treatment plan. (step 720). The changes may be accomplished manually or automatically and may comprise adding treatment sites, deleting treatment sites, repeating treatment sites, or modifying specific thermal dose properties for some or all of the treatment sites.
There are several methods that are used to change or update the treatment plan. For example, at the end of each thermal dose, there may be regions within the target layer that are not covered by accumulated dose contours. These untreated areas are separated into individual regions. Each of these regions is then sent through the process, beginning with step 708, resulting in an updated treatment plan constructed to treat the remaining regions. The process will repeat until there are no more untreated regions.
In order to accomplish the tracking of untreated regions, each treatment region may be maintained as a two-dimensional linked list of pixel ranges sorted by (y) and then (x) coordinates as illustrated in FIGS. 10A-C. As can be seen in FIG. 10A, the treatment region is a continuous region 802 represented by the lighter pixels. The pixel distribution is then represented by the data structure 804. This type of representation is called “run-length encoding.” The data structure 804 contains linked lists 806 by row indicating the pixels that contain treatment region 802. Thus, for row 1, list element 806a indicates that the pixel range from 1 to 2 contains a portion of treatment region 802, 806b indicates that the pixel range from 7 to 7 contains a portion of treatment region 802, and 806c indicates that the pixel range from 11 to 11 contains a portion of treatment region 802. It can also be seen that rows 0 and 5 do not contain any portion of treatment region 802; therefore, these rows in data structure 804 do not contain any pixel ranges.
Once a thermal dose is applied, the area of the target mass that is destroyed (the treated region) is represented in the same fashion as the untreated region shown in FIG. 10A. The treated region (FIG. 10B) is subtracted from the untreated region in order to define the remaining untreated region within treatment region 802. These areas can then be sent back to the planning stage (step 720) and the treatment plan can be updated.
Subtraction of the run-lengths representing untreated region and the treated-region follows the following rules:
For run-length segments [a,b] and [c,d],
[a,b] − [c,d] = c > b or d < a [a,b] (1)
c <= a and d >= b 0 (2)
c > a and d >= b [a, c − 1] (3)
c <= a and d < b [d + 1, b] (4)
c > a and d < b [a, c − 1] and [d + 1, b] (5)
The subtraction, therefore, of two regions involves traversing the lines in each region and subtracting a line in the first data structure from its corresponding line in the second data structure.
The above rules will be further explained by means of an example in which region 808 illustrated in FIG. 10B, and represented by data structure 810, will be subtracted from region 802 in FIG. 10A. Application of rules (1)-(5), for the given regions, results in the following:
(Step 1) Top Row:
[1,2] − [1,2] = 0 Rule (2)
[7,7] − [1,2] = [7,7], [7,7] − [6,11] = 0 Rules (1), (2)
[11,11] − [1,2] = [11,11], [11,11] − [6,11] = 0 Rules (1), (2)
(Step 2) Second Row:
[1,3] − [2,3] = [1,1], [1,1] − [7,7] = [1,1], [1,1] − Rules (3), (1), (1)
[11,11] = [1,1]
[7,11] − [2,3] = [7,11], [7,11] − [7,7] = [7,11], [7,11] − Rules (1), (1), (3)
[11,11] = [7,10]
(Step 3) Third Row:
[1,11] − [1,11] = 0 Rule (2)
(Step 4) Lower Row:
[1,10] − [4,9] = [1,3] and [10,10] Rule (5)
In performing the subtraction, each segment 806d and 806e in row 1 of data structure 810 is subtracted from each segment 806a, 806b, and 806c in row 1 of data structure 804. Thus, as can be seen for the top row under Step 1 above, segment 806d is subtracted from segment 806a using Rule (2). The application of Rule (2) results in a run-length segment that contains no pixels, i.e., a range of 0. Intuitively, it can be seen that segment 806d is the same as segment 806a and that subtraction of the two should result in 0, as it does under Rule (2). Next, segment 806d is subtracted from segment 806b, using Rule (1). Intuitively, because the pixel range described by segment 806d does not overlap the range described by segment 806b, subtracting 806d from 806b should have no effect. Indeed, application of rule (1) has no effect on segment 806b.
Now, however, segment 806e must be subtracted from segment 806b. As can be seen, segment 806e overlaps segment 806b entirely. Therefore, application of rule (2), which is the appropriate rule for these two segments, results in 0. In other words, if region 802 is a target mass, and region 808 defines an expected thermal dose, then the dose represented by segment 806e will completely ablate the portion of the target mass represented by segment 806b. The same result occurs for the subtraction of segments 806e and 806d from segment 806c. The subtraction then continues for each row as illustrated by steps 2, 3, and 4 above. The resulting region is illustrated in FIG. 10C, which actually consists of four separate regions 812, 814, 816, and 818. These regions 812, 814, 816, and 818 are represented by data structure 820 and associated linked lists of run-length segments 806. It is these untreated regions 812, 814, 816, and 818 that will require the treatment plan to be updated by returning to the planning stage in step 720.
An alternative method for updating the treatment plan involves eliminating steps 710 and 712 in FIG. 9. Instead, the system accepts a target mass 914 to be treated and follows the steps illustrated in FIG. 11. First, in step 902, it is determined if there is an untreated region 914. If there is, then treatment site 916 is selected in step 904, and thermal dose properties are estimated so as to deliver the appropriate thermal dose the treatment site 916. Then, in step 906, the thermal dose is applied to treatment site 916 resulting in a treated region 918. In step 908, the size of treated region is calculated and stored as a linked-list so that in step 910 the treated region can be subtracted from the untreated region 920 in order to determine the remaining untreated region. The process then reverts to step 902, and a new treatment site is selected. Once the entire target mass 914 is treated, there will not be any untreated regions and the process will exit.
Referring back to FIG. 9, after the treatment is complete, it is determined in step 726 whether to restart a treatment or to exit. Additionally, if there is insufficient information or a fatal error occurs in any of steps 704-716, the process will automatically go to step 726, where it can be decide to proceed with a new treatment plan or to exit altogether.
Thus, on a most detailed and narrow aspect, the invention provides methods for constructing a three-dimensional thermal dose treatment plan, including:
    • (a) receiving diagnostic images;
    • (b) defining a target region;
    • (c) defining a treatment line that cuts through the target mass perpendicular to the surface of the heat applying element and extending from the nearest point within the target mass to the farthest;
    • (d) determining the maximal power required for a large and small focal spots at the furthest point;
    • (e) determining if the corresponding maximal temperatures for the large and small focal spots exceed the allowed limits;
    • (f) scaling the maximal power down until the maximal temperature is within the allowable limits, thus providing a scaled maximal power;
    • (g) using the scaled maximal power from the previous step to find maximal powers for any intermediate focal spot sizes;
    • (h) using the scaled maximal power to find the maximal powers for each focal spot size at the nearest point within the target mass along the treatment line;
    • (i) assuming the thermal dose is focused at a first point between the nearest point and farthest point, but preferably close to the nearest point;
    • (j) using the scaled maximal power to find maximal temperatures and a lesion size, corresponding to an appropriate focal spot size and required maximal power at the first point;
    • (k) determining if the maximal temperature at the first point is greater than the allowable limits;
    • (l) scaling down the maximal power at the first point so that the maximal temperature will not exceed the allowed limits;
    • (m) finding the corresponding lesion size at the first point;
    • (n) placing a first treatment slice using an overlap criterion with respect to a boundary defined by the nearest point in the target mass;
    • (o) placing an auxiliary treatment slice on top of the first treatment using an inter-layer overlap criterion; and
    • (p) replacing the nearest point with the first point and returning to step (h) to repeat the process until the target region is covered from the nearest point to the farthest point along the treatment line.
Although many aspects and features of the present invention have been described and illustrated in the above description and drawings of the preferred embodiments, it is understood that numerous changes and modifications can be made by those skilled in the art without departing from the invention concepts disclosed herein.
The invention, therefore, is not to be restricted, except by the following claims and their equivalents.

Claims (67)

1. A thermal treatment system, comprising:
a heat applying element for generating a delivering thermal dose doses used to ablate a target mass in a patient;
a controller for controlling thermal dose properties of the heat applying element;
an imager for providing preliminary images of the target mass; and
a planner for automatically constructing a treatment plan, the treatment plan comprising a series of treatment sites that are each represented by a set of thermal dose properties;
wherein the planner automatically constructs the treatment plan based on input information including one or more of:
a volume of the target mass,
a distance from a skin surface of the patient to the target mass,
a set of default thermal dose prediction properties,
a set of user specified thermal dose prediction properties,
physical properties of the heat applying elements, and
images provided by the imager.
2. The treatment system of claim 1, wherein the thermal dose properties translate, at least in part, to electrical and mechanical properties of the heat applying element.
3. The treatment system of claim 1, wherein the default thermal dose prediction properties are based on a type of clinical application and include at least one of:
thermal dose threshold,
thermal dose prediction algorithm,
maximum allowed energy for each thermal dose,
thermal dose duration for each treatment site,
cooling time between thermal doses, and
electrical properties for the heat applying element.
4. The treatment system of claim 1, wherein the user specified thermal close dose prediction properties include at least one of:
overrides for any default thermal dose prediction properties,
treatment site grid density, and
thermal dose prediction properties not specified as default thermal dose prediction properties selected from the group comprised consisting of thermal dose threshold, thermal dose prediction algorithm, maximum allowed energy for each thermal dose, thermal dose duration for each treatment site cooling time between thermal doses, and electrical properties for the heat applying element.
5. The treatment system of claim 1, wherein the treatment plan ensures that the entire target mass is covered by a series of thermal doses so as to obtain a composite thermal dose sufficient to ablate the entire target mass.
6. The treatment system of claim 1, wherein the thermal dose properties are automatically optimized using physiological properties as the optimization criterion.
7. The treatment system of claim 1, wherein the planner limits the thermal dose at each treatment site in order to prevent carbonization or evaporation.
8. The treatment system of claim 1, wherein the planner constructs a predicted thermal dose distribution illustrating the predicted thermal dose contours of each treatment site in the treatment plan.
9. The treatment system of claim 1, further comprising a User Interface (UI) for entering user specified thermal dose prediction properties and for editing the treatment plan once the treatment plan is constructed.
10. The treatment system of claim 1, wherein the treatment plan is constructed in three dimensions.
11. The treatment system of claim 1, further comprising a feedback imager for providing thermal images illustrating the an actual thermal dose distribution resulting from a respective thermal dose delivery at each treatment site.
12. The treatment system of claim 11, wherein the imager acts as the feedback imager.
13. The treatment system of claim 1, wherein the heat applying element applies one of the following:
ultrasound energy,
laser light energy,
RF energy,
microwave energy, and
electrical energy.
14. A focused ultrasound system, comprising:
a transducer for generating delivering successive delivered thermal doses of ultrasound energy that results in thermal doses to ablate for ablating a target mass in a patient;
a controller for controlling thermal dose properties of the transducer;
an imager for providing preliminary images of the target mass, and for providing thermal images illustrating an actual thermal dose distribution in the patient resulting from a delivered thermal dose of ultrasound energy to the target mass; and
a planner configured for automatically constructing a treatment plan using the preliminary images, the treatment plan comprising a series of predicted thermal doses to treatment sites represented by a set of thermal dose properties used by a controller to control the transducer of the target mass;
wherein the planner further constructs a predicted thermal dose distribution illustrating the predicted thermal dose contours of each treatment site in the treatment plan;
wherein after a thermal dose is delivered to each treatment site in the treatment plan, the actual thermal dose distribution is compared to the predicted thermal dose distribution to determine remaining untreated locations within the target mass.
15. The focused ultrasound system of claim 14, wherein after a thermal dose is delivered to a treatment site in the treatment plan, the comparison of the actual thermal dose distribution is compared to the predicted thermal dose distribution is used to determine changes to the dosing parameters in neighboring sonication sites treatment plan for treating the remaining untreated locations.
16. The focused ultrasound system of claim 14, wherein the planner automatically evaluates the treatment plan based on the remaining untreated locations and updates, in order to ensure complete ablation of the target mass, either changes the treatment plan to ensure complete ablation of the target mass is achieved by one or more of adding treatment sites, removing treatment sites, modifying existing treatment sites, or leaving leaves the treatment plan unchanged, based on the comparison of the actual thermal dose distribution to the predicted thermal dose distribution.
17. The focused ultrasound system of claim 14, wherein a user can manually adjust the treatment plan based on the remaining untreated locations.
18. The focused ultrasound system of claim 14, wherein the preliminary images and the thermal images represent three-dimensional data.
19. The focused ultrasound system of claim 14, wherein the predicted thermal dose distribution and actual thermal dose distribution represent three-dimensional data.
20. The focused ultrasonic system of claim 14, wherein the imager further provides outlines of sensitive regions within the patient where ultrasonic waves are not allowed to pass that are sensitive to ultrasound.
21. The focused ultrasonic system of claim 20, wherein the processor planner uses the outlines in constructing the treatment plan so as to avoid exposing the sensitive regions to ultrasound.
22. The focused ultrasound system of claim 20 21, wherein the sensitive regions comprise bones, gas, and other sensitive tissues.
23. The focused ultrasound system of claim 14, wherein based on the comparison of the actual thermal dose distribution to the predicted thermal dose distribution for a given treatment site, the planner adjusts the treatment plan to include delivery of an additional thermal dose to the same or substantially the same treatment site.
24. A thermal treatment system, comprising:
a heat applying element for delivering thermal doses to ablate a target mass in a patient;
a controller for controlling thermal dose properties of the heat applying element;
an imager for providing preliminary images of the target mass; and
a planner for automatically constructing a treatment plan, the treatment plan comprising a series of treatment sites that are each represented by a set of thermal dose properties,
wherein the planner automatically constructs the treatment plan based on input information including thermal dose prediction properties comprising at least one of
a set of default thermal dose prediction properties, or
a set of user specified thermal dose prediction properties.
25. The treatment system of claim 24, wherein the thermal dose properties translate, at least in part, to electrical and mechanical properties of the heat applying element.
26. The treatment system of claim 24, wherein the default thermal dose prediction properties are based on a type of clinical application and include at least one of:
thermal dose threshold,
thermal dose prediction algorithm,
maximum allowed energy for each thermal dose,
thermal dose duration for each treatment site,
cooling time between thermal doses, and
electrical properties for the heat applying element.
27. The treatment system of claim 24, wherein the user specified thermal dose prediction properties include at least one of:
overrides for any default thermal dose prediction properties,
treatment site grid density, and
thermal dose prediction properties not specified as default thermal dose prediction properties and selected from the group consisting of thermal dose threshold, thermal dose prediction algorithm, maximum allowed energy for each thermal dose, thermal dose duration for each treatment site cooling time between thermal doses, and electrical properties for the heat applying element.
28. The treatment system of claim 24, wherein the treatment plan ensures that the entire target mass is covered by a series of thermal doses so as to obtain a composite thermal dose sufficient to ablate the entire target mass.
29. The treatment system of claim 24, wherein the thermal dose properties are automatically optimized using physiological properties as the optimization criterion.
30. The treatment system of claim 24, wherein the planner limits the thermal dose at each treatment site in order to prevent carbonization or evaporation.
31. The treatment system of claim 24, wherein the planner constructs a predicted thermal dose distribution illustrating the predicted thermal dose contours of each treatment site in the treatment plan.
32. The treatment system of claim 24, further comprising a user interface for entering user specified thermal dose prediction properties and for editing the treatment plan once the treatment plan is constructed.
33. The treatment system of claim 24, wherein the treatment plan is constructed in three dimensions.
34. The treatment system of claim 24, wherein the imager provides thermal images illustrating an actual thermal dose distribution resulting from a respective thermal dose delivery at each treatment site.
35. The treatment system of claim 24, wherein the heat applying element applies one of the following:
ultrasound energy,
laser light energy,
RF energy,
microwave energy, and
electrical energy.
36. The treatment system of claim 24, wherein the input information further includes a volume of the target tissue mass.
37. A method of treating a target tissue mass in a patient using a focused ultrasound system, the system comprising a transducer for delivering thermal doses of ultrasound energy to the target tissue mass, an imager for providing images of the target mass, a controller for controlling the transducer, and a planner for constructing a treatment plan, the method comprising
obtaining preliminary images of the target tissue mass; and
based on the preliminary images, constructing a treatment plan for ablating the target mass, the treatment plan comprising a series of treatment sites in the target mass that are to each receive a thermal dose of ultrasound energy from the transducer, each treatment site represented by a set of thermal dose properties to be used by the controller to control the delivery of ultrasound energy by the transducer.
38. The method of claim 37, further comprising constructing a predicted thermal dose distribution illustrating the predicted thermal dose contours of each treatment site in the treatment plan.
39. The method of claim 37, further comprising delivering thermal doses of ultrasound energy to one or more of the treatment sites.
40. The method of claim 37, wherein the imager provides thermal images illustrating an actual thermal dose distribution in the target tissue mass resulting from a thermal dose of ultrasound energy to a treatment site, the method further comprising
constructing a predicted thermal dose distribution illustrating the predicted thermal dose contours of each treatment site in the treatment plan,
delivering thermal doses of ultrasound energy to the treatment sites according to the treatment plan, and
after a thermal dose is delivered to a treatment site in the treatment plan, comparing the actual thermal dose distribution to the predicted thermal dose distribution for the treatment site.
41. The method of claim 40, further comprising, based on the comparison of the actual thermal dose distribution to the predicted thermal dose distribution, selectively changing the treatment plan by one or more of adding treatment sites, removing treatment sites, and modifying treatment sites, to ensure complete ablation of the target mass.
42. The method of claim 40, further comprising, based on the comparison of the actual thermal dose distribution to the predicted thermal dose distribution, delivering an additional thermal dose of ultrasound energy to the same or substantially the same treatment site.
43. The method of claim 37, further comprising manually adjusting the treatment plan.
44. The method of claim 37, further comprising:
identifying in images used to construct the treatment plan outlines of regions within the patient that are sensitive to the application of ultrasound, and
constructing the treatment plan so as to avoid exposure of the sensitive regions to ultrasound energy delivered by the transducer.
45. The method of claim 37, wherein the thermal dose properties translate, at least in part, to electrical and mechanical properties of the transducer.
46. The method of claim 37, wherein the treatment plan ensures that the entire target mass is covered by a series of thermal doses of ultrasound energy so as to obtain a composite thermal dose sufficient to ablate the entire target mass.
47. The method of claim 37, further comprising optimizing the thermal dose properties based on physiological properties as optimization criterion.
48. A method for treating a target tissue mass in a patient using a thermal energy treatment system, the system comprising a heat applying element for delivering thermal doses used to ablate the target mass, a controller for controlling thermal dose properties of the heat applying element, an imager for providing images of the target mass, and a planner for constructing a treatment plan, the method comprising:
receiving input information including preliminary images of the target mass; and
based on the input information, automatically constructing a treatment plan for ablating the target mass, the treatment plan comprising a series of treatment sites in the target mass that are to each receive a thermal dose from the heat applying element, each treatment site represented by a set of thermal dose properties to be used by the controller to control the delivery of the thermal doses.
49. The method of claim 48, further comprising automatically constructing a predicted thermal dose distribution illustrating the predicted thermal dose contours of each treatment site in the treatment plan.
50. The method of claim 48, further comprising delivering thermal doses from the heat applying element to one or more of the treatment sites.
51. The method of claim 48, wherein the imager provides thermal images illustrating an actual thermal dose distribution in the target tissue mass resulting from a thermal dose delivered to a treatment site, the method further comprising
constructing a predicted thermal dose distribution illustrating the predicted thermal dose contours of each treatment site in the treatment plan,
delivering thermal doses to the treatment sites according to the treatment plan, and
after a thermal dose is delivered to a treatment site in the treatment plan, comparing the actual thermal dose distribution to the predicted thermal dose distribution for the treatment site.
52. The method of claim 51, further comprising, based on the comparison of the actual thermal dose distribution to the predicted thermal dose distribution, changing the treatment plan by one or more of adding treatment sites, removing treatment sites, and modifying treatment sites, to ensure complete ablation of the target mass.
53. The method of claim 51, further comprising, based on the comparison of the actual thermal dose distribution to the predicted thermal dose distribution, leaving the treatment plan unchanged in order to ensure complete ablation of the target mass.
54. The method of claim 51, further comprising, based on the comparison of the actual thermal dose distribution to the predicted thermal dose distribution, delivering an additional thermal dose to the same or substantially the same treatment site.
55. The method of claim 48, further comprising manually adjusting the treatment plan.
56. The method of claim 48, wherein the thermal dose properties translate, at least in part, to electrical and mechanical properties of the heat applying element.
57. The method of claim 48, wherein the treatment plan ensures that the entire target mass is covered by a series of thermal doses so as to obtain a composite thermal dose sufficient to ablate the entire target mass.
58. The method of claim 48, further comprising optimizing the thermal dose properties based on physiological properties as optimization criterion.
59. The method of claim 48, wherein the input information further includes one or more of the group consisting of:
a volume of the target mass,
default thermal dose prediction properties, and
user specified thermal dose prediction properties.
60. The method of claim 53, wherein the heat applying element applies one of the following:
ultrasound energy,
laser light energy,
RF energy,
microwave energy, and
electrical energy.
61. A method of treating a target tissue mass in a patient using a focused ultrasound system, the system comprising a transducer for delivering thermal doses of ultrasound energy to the target tissue mass, an imager for providing images of the target mass, a controller for controlling the transducer, and a planner for constructing a treatment plan, the method comprising
obtaining preliminary images of the target tissue mass;
based on the preliminary images, automatically constructing, with the planner, a treatment plan for ablating the target mass, the treatment plan comprising a series of treatment sites in the target mass that are to each receive a thermal dose of ultrasound energy from the transducer, each treatment site represented by a set of thermal dose properties to be used by the controller to control the delivery of ultrasound energy by the transducer;
constructing a predicted thermal dose distribution illustrating the predicted thermal dose contours of the treatment sites in the treatment plan; and
delivering thermal doses of ultrasound energy to the treatment sites according to the treatment plan,
wherein the imager provides thermal images illustrating an actual thermal dose distribution in the target tissue mass resulting from a thermal dose delivered to a treatment site, and
wherein after a thermal dose is delivered to each treatment site, the actual thermal dose distribution is compared to the predicted thermal dose distribution to determine remaining untreated locations within the target mass.
62. The method of claim 61, wherein the comparison of the actual thermal dose distribution to the predicted thermal dose distribution is used to determine changes to the treatment plan for treating the remaining untreated locations.
63. The method of claim 61, wherein the planner automatically evaluates the treatment plan based on the remaining untreated locations and, in order to ensure complete ablation of the target mass, either changes the treatment plan by one or more of adding treatment sites, removing treatment sites, and modifying existing treatment sites, or leaves the treatment plan unchanged.
64. The method of claim 61, further comprising manually adjusting the treatment plan based on the remaining untreated locations.
65. The method of claim 61, wherein the preliminary images and the thermal images represent three-dimensional data.
66. The method of claim 61, wherein the predicted thermal dose distribution and actual thermal dose distribution represent three-dimensional data.
67. The method of claim 61, wherein the imager further provides outlines of regions within the patient that are sensitive to ultrasound, and wherein the planner uses the outlines in constructing the treatment plan so as to avoid exposing the sensitive regions to ultrasound.
US11/223,907 2000-11-28 2005-09-08 Apparatus for controlling thermal dosing in a thermal treatment system Expired - Lifetime USRE43901E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/223,907 USRE43901E1 (en) 2000-11-28 2005-09-08 Apparatus for controlling thermal dosing in a thermal treatment system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/724,670 US6618620B1 (en) 2000-11-28 2000-11-28 Apparatus for controlling thermal dosing in an thermal treatment system
US11/223,907 USRE43901E1 (en) 2000-11-28 2005-09-08 Apparatus for controlling thermal dosing in a thermal treatment system

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/724,670 Reissue US6618620B1 (en) 2000-11-28 2000-11-28 Apparatus for controlling thermal dosing in an thermal treatment system

Publications (1)

Publication Number Publication Date
USRE43901E1 true USRE43901E1 (en) 2013-01-01

Family

ID=24911369

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/724,670 Ceased US6618620B1 (en) 2000-11-28 2000-11-28 Apparatus for controlling thermal dosing in an thermal treatment system
US11/223,907 Expired - Lifetime USRE43901E1 (en) 2000-11-28 2005-09-08 Apparatus for controlling thermal dosing in a thermal treatment system

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/724,670 Ceased US6618620B1 (en) 2000-11-28 2000-11-28 Apparatus for controlling thermal dosing in an thermal treatment system

Country Status (6)

Country Link
US (2) US6618620B1 (en)
EP (1) EP1349612B1 (en)
JP (1) JP4080332B2 (en)
CN (1) CN1293926C (en)
AU (1) AU2002218462A1 (en)
WO (1) WO2002043804A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100280356A1 (en) * 2008-01-14 2010-11-04 Koninklijke Philips Electronics N.V. Therapy system with temperature control
US20120070058A1 (en) * 2009-06-02 2012-03-22 Koninklijke Philips Electronics N.V. Mr imaging guided therapy
US8979871B2 (en) 2009-08-13 2015-03-17 Monteris Medical Corporation Image-guided therapy of a tissue
US20150141874A1 (en) * 2013-11-18 2015-05-21 Kitchener Clark Wilson Multi-beam Ultrasound Device
US9333038B2 (en) 2000-06-15 2016-05-10 Monteris Medical Corporation Hyperthermia treatment and probe therefore
US9433383B2 (en) 2014-03-18 2016-09-06 Monteris Medical Corporation Image-guided therapy of a tissue
US9504484B2 (en) 2014-03-18 2016-11-29 Monteris Medical Corporation Image-guided therapy of a tissue
US9981148B2 (en) 2010-10-22 2018-05-29 Insightec, Ltd. Adaptive active cooling during focused ultrasound treatment
US10327830B2 (en) 2015-04-01 2019-06-25 Monteris Medical Corporation Cryotherapy, thermal therapy, temperature modulation therapy, and probe apparatus therefor
US10675113B2 (en) 2014-03-18 2020-06-09 Monteris Medical Corporation Automated therapy of a three-dimensional tissue region
US10835215B2 (en) 2012-09-12 2020-11-17 Convergent Life Sciences, Inc. Method and apparatus for laser ablation under ultrasound guidance

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6050943A (en) 1997-10-14 2000-04-18 Guided Therapy Systems, Inc. Imaging, therapy, and temperature monitoring ultrasonic system
US8527046B2 (en) 2000-04-20 2013-09-03 Medtronic, Inc. MRI-compatible implantable device
US6618620B1 (en) 2000-11-28 2003-09-09 Txsonics Ltd. Apparatus for controlling thermal dosing in an thermal treatment system
US7914453B2 (en) 2000-12-28 2011-03-29 Ardent Sound, Inc. Visual imaging system for ultrasonic probe
US7846096B2 (en) 2001-05-29 2010-12-07 Ethicon Endo-Surgery, Inc. Method for monitoring of medical treatment using pulse-echo ultrasound
US20030013972A1 (en) 2001-05-29 2003-01-16 Makin Inder Raj. S. Treatment of lung lesions using ultrasound
US7001413B2 (en) * 2002-07-03 2006-02-21 Life Support Technologies, Inc. Methods and apparatus for light therapy
US7201766B2 (en) * 2002-07-03 2007-04-10 Life Support Technologies, Inc. Methods and apparatus for light therapy
US20040064050A1 (en) * 2002-09-20 2004-04-01 Jun Liu System and method for screening tissue
US8088067B2 (en) 2002-12-23 2012-01-03 Insightec Ltd. Tissue aberration corrections in ultrasound therapy
JP2006521902A (en) * 2003-03-31 2006-09-28 ライポソニックス, インコーポレイテッド Vortex transducer
US7611462B2 (en) 2003-05-22 2009-11-03 Insightec-Image Guided Treatment Ltd. Acoustic beam forming in phased arrays including large numbers of transducer elements
US7311701B2 (en) * 2003-06-10 2007-12-25 Cierra, Inc. Methods and apparatus for non-invasively treating atrial fibrillation using high intensity focused ultrasound
US8251057B2 (en) 2003-06-30 2012-08-28 Life Support Technologies, Inc. Hyperbaric chamber control and/or monitoring system and methods for using the same
US20050080469A1 (en) * 2003-09-04 2005-04-14 Larson Eugene A. Treatment of cardiac arrhythmia utilizing ultrasound
CA2546265A1 (en) * 2003-12-30 2005-07-21 Liposonix, Inc. Systems and methods for the destruction of adipose tissue
US7857773B2 (en) * 2003-12-30 2010-12-28 Medicis Technologies Corporation Apparatus and methods for the destruction of adipose tissue
US8337407B2 (en) * 2003-12-30 2012-12-25 Liposonix, Inc. Articulating arm for medical procedures
US20050154309A1 (en) * 2003-12-30 2005-07-14 Liposonix, Inc. Medical device inline degasser
US20050193451A1 (en) * 2003-12-30 2005-09-01 Liposonix, Inc. Articulating arm for medical procedures
US20050154308A1 (en) 2003-12-30 2005-07-14 Liposonix, Inc. Disposable transducer seal
CA2551348A1 (en) * 2003-12-30 2005-07-21 Liposonix, Inc. Ultrasound therapy head with movement control
US7662114B2 (en) * 2004-03-02 2010-02-16 Focus Surgery, Inc. Ultrasound phased arrays
US7247141B2 (en) * 2004-03-08 2007-07-24 Ethicon Endo-Surgery, Inc. Intra-cavitary ultrasound medical system and method
US20050240123A1 (en) * 2004-04-14 2005-10-27 Mast T D Ultrasound medical treatment system and method
EP1755458B1 (en) * 2004-05-06 2015-02-25 Focus Surgery, Inc. Apparatus for the selective treatment of tissue
US7883468B2 (en) 2004-05-18 2011-02-08 Ethicon Endo-Surgery, Inc. Medical system having an ultrasound source and an acoustic coupling medium
US7951095B2 (en) 2004-05-20 2011-05-31 Ethicon Endo-Surgery, Inc. Ultrasound medical system
US7695436B2 (en) * 2004-05-21 2010-04-13 Ethicon Endo-Surgery, Inc. Transmit apodization of an ultrasound transducer array
US7761945B2 (en) 2004-05-28 2010-07-27 Life Support Technologies, Inc. Apparatus and methods for preventing pressure ulcers in bedfast patients
US7806839B2 (en) 2004-06-14 2010-10-05 Ethicon Endo-Surgery, Inc. System and method for ultrasound therapy using grating lobes
US7699780B2 (en) 2004-08-11 2010-04-20 Insightec—Image-Guided Treatment Ltd. Focused ultrasound system with adaptive anatomical aperture shaping
CN100522287C (en) * 2004-08-17 2009-08-05 伽玛星医疗工业(上海)有限公司 Focusing type gamma ray therapeutic method and arrangement
US8409099B2 (en) * 2004-08-26 2013-04-02 Insightec Ltd. Focused ultrasound system for surrounding a body tissue mass and treatment method
US20060047281A1 (en) 2004-09-01 2006-03-02 Syneron Medical Ltd. Method and system for invasive skin treatment
US9011336B2 (en) 2004-09-16 2015-04-21 Guided Therapy Systems, Llc Method and system for combined energy therapy profile
US7393325B2 (en) 2004-09-16 2008-07-01 Guided Therapy Systems, L.L.C. Method and system for ultrasound treatment with a multi-directional transducer
US7824348B2 (en) 2004-09-16 2010-11-02 Guided Therapy Systems, L.L.C. System and method for variable depth ultrasound treatment
US8444562B2 (en) 2004-10-06 2013-05-21 Guided Therapy Systems, Llc System and method for treating muscle, tendon, ligament and cartilage tissue
US10864385B2 (en) 2004-09-24 2020-12-15 Guided Therapy Systems, Llc Rejuvenating skin by heating tissue for cosmetic treatment of the face and body
US8535228B2 (en) 2004-10-06 2013-09-17 Guided Therapy Systems, Llc Method and system for noninvasive face lifts and deep tissue tightening
US20060111744A1 (en) 2004-10-13 2006-05-25 Guided Therapy Systems, L.L.C. Method and system for treatment of sweat glands
ES2705758T3 (en) * 2004-10-06 2019-03-26 Guided Therapy Systems Llc System for controlled heat treatment of human surface tissue
JP2008522642A (en) 2004-10-06 2008-07-03 ガイデッド セラピー システムズ, エル.エル.シー. Method and system for beauty enhancement
US8133180B2 (en) 2004-10-06 2012-03-13 Guided Therapy Systems, L.L.C. Method and system for treating cellulite
US11235179B2 (en) 2004-10-06 2022-02-01 Guided Therapy Systems, Llc Energy based skin gland treatment
US8663112B2 (en) 2004-10-06 2014-03-04 Guided Therapy Systems, Llc Methods and systems for fat reduction and/or cellulite treatment
US9827449B2 (en) 2004-10-06 2017-11-28 Guided Therapy Systems, L.L.C. Systems for treating skin laxity
US11883688B2 (en) 2004-10-06 2024-01-30 Guided Therapy Systems, Llc Energy based fat reduction
US9694212B2 (en) 2004-10-06 2017-07-04 Guided Therapy Systems, Llc Method and system for ultrasound treatment of skin
DE202005022028U1 (en) 2004-10-06 2012-07-09 Guided Therapy Systems, Llc Ultrasonic tissue treatment system
US8690778B2 (en) 2004-10-06 2014-04-08 Guided Therapy Systems, Llc Energy-based tissue tightening
US7758524B2 (en) 2004-10-06 2010-07-20 Guided Therapy Systems, L.L.C. Method and system for ultra-high frequency ultrasound treatment
US11207548B2 (en) 2004-10-07 2021-12-28 Guided Therapy Systems, L.L.C. Ultrasound probe for treating skin laxity
US11724133B2 (en) 2004-10-07 2023-08-15 Guided Therapy Systems, Llc Ultrasound probe for treatment of skin
US20110015549A1 (en) * 2005-01-13 2011-01-20 Shimon Eckhouse Method and apparatus for treating a diseased nail
US8801701B2 (en) * 2005-03-09 2014-08-12 Sunnybrook Health Sciences Centre Method and apparatus for obtaining quantitative temperature measurements in prostate and other tissue undergoing thermal therapy treatment
US7771418B2 (en) * 2005-03-09 2010-08-10 Sunnybrook Health Sciences Centre Treatment of diseased tissue using controlled ultrasonic heating
EP1875327A2 (en) 2005-04-25 2008-01-09 Guided Therapy Systems, L.L.C. Method and system for enhancing computer peripheral saftey
US8038631B1 (en) 2005-06-01 2011-10-18 Sanghvi Narendra T Laparoscopic HIFU probe
US20070016039A1 (en) * 2005-06-21 2007-01-18 Insightec-Image Guided Treatment Ltd. Controlled, non-linear focused ultrasound treatment
US20070038096A1 (en) * 2005-07-06 2007-02-15 Ralf Seip Method of optimizing an ultrasound transducer
WO2007085892A2 (en) 2005-11-23 2007-08-02 Insightec, Ltd Hierarchical switching in ultra-high density ultrasound array
US8548562B2 (en) * 2006-04-04 2013-10-01 John Trachtenberg System and method of guided treatment within malignant prostate tissue
US8235901B2 (en) 2006-04-26 2012-08-07 Insightec, Ltd. Focused ultrasound system with far field tail suppression
FR2903316B1 (en) * 2006-07-05 2009-06-26 Edap S A THERAPY PROBE AND THERAPY APPARATUS INCLUDING SUCH A PROBE
US10376314B2 (en) * 2006-07-14 2019-08-13 Neuwave Medical, Inc. Energy delivery systems and uses thereof
CN101511295B (en) * 2006-07-14 2012-09-05 纽华沃医药公司 Energy delivery systems and uses thereof
US7652410B2 (en) * 2006-08-01 2010-01-26 Insightec Ltd Ultrasound transducer with non-uniform elements
US7871406B2 (en) 2006-08-04 2011-01-18 INTIO, Inc. Methods for planning and performing thermal ablation
EP2068736A4 (en) * 2006-08-04 2009-12-30 Abla Tx Inc Methods and systems for planning, performing and monitoring thermal ablation
US8155416B2 (en) 2008-02-04 2012-04-10 INTIO, Inc. Methods and apparatuses for planning, performing, monitoring and assessing thermal ablation
US8556888B2 (en) 2006-08-04 2013-10-15 INTIO, Inc. Methods and apparatuses for performing and monitoring thermal ablation
US8043235B2 (en) * 2006-08-22 2011-10-25 Schwartz Donald N Ultrasonic treatment of glaucoma
FR2905277B1 (en) * 2006-08-29 2009-04-17 Centre Nat Rech Scient DEVICE FOR THE VOLUMIC TREATMENT OF BIOLOGICAL TISSUES
US7955281B2 (en) * 2006-09-07 2011-06-07 Nivasonix, Llc External ultrasound lipoplasty
US9566454B2 (en) 2006-09-18 2017-02-14 Guided Therapy Systems, Llc Method and sysem for non-ablative acne treatment and prevention
US7559905B2 (en) 2006-09-21 2009-07-14 Focus Surgery, Inc. HIFU probe for treating tissue with in-line degassing of fluid
CN101234234B (en) * 2007-01-30 2011-11-16 西门子公司 Automatic selection method for region of interest of covering heating region
US8287471B2 (en) * 2007-02-20 2012-10-16 National Health Research Institutes Medical treatment using an ultrasound phased array
US8142200B2 (en) * 2007-03-26 2012-03-27 Liposonix, Inc. Slip ring spacer and method for its use
JP2010526589A (en) 2007-05-07 2010-08-05 ガイデッド セラピー システムズ, エル.エル.シー. Method and system for modulating a mediant using acoustic energy
US20150174388A1 (en) 2007-05-07 2015-06-25 Guided Therapy Systems, Llc Methods and Systems for Ultrasound Assisted Delivery of a Medicant to Tissue
US8235902B2 (en) 2007-09-11 2012-08-07 Focus Surgery, Inc. System and method for tissue change monitoring during HIFU treatment
US8251908B2 (en) 2007-10-01 2012-08-28 Insightec Ltd. Motion compensated image-guided focused ultrasound therapy system
WO2009049148A1 (en) * 2007-10-11 2009-04-16 Boston Scientific Scimed, Inc. Device and method for detecting and treating lesions
EP2561819B1 (en) 2008-01-17 2015-01-07 Syneron Medical Ltd. Hair removal apparatus for personal use
MX2010007407A (en) 2008-01-24 2010-08-16 Syneron Medical Ltd A device, apparatus, and method of adipose tissue treatment.
KR20100120188A (en) 2008-02-01 2010-11-12 메디시스 테크놀로지스 코포레이션 Therapy head for use with an ultrasound system
US8133222B2 (en) 2008-05-28 2012-03-13 Medwaves, Inc. Tissue ablation apparatus and method using ultrasonic imaging
KR102147455B1 (en) 2008-06-06 2020-08-24 얼테라, 인크 Ultrasound treatment system
US20100017750A1 (en) 2008-07-16 2010-01-21 Avner Rosenberg User interface
US9314293B2 (en) 2008-07-16 2016-04-19 Syneron Medical Ltd RF electrode for aesthetic and body shaping devices and method of using same
JP5887137B2 (en) * 2008-09-09 2016-03-16 コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. Treatment system to administer energy
WO2010029474A1 (en) * 2008-09-09 2010-03-18 Koninklijke Philips Electronics N.V. Therapy system for depositing energy
DE102008047644B4 (en) * 2008-09-17 2015-09-10 Siemens Aktiengesellschaft Method for registering two imaging modalities
BRPI0917921A2 (en) 2008-09-21 2015-11-10 Syneron Medical Ltd method and apparatus for personal skin care
US9050449B2 (en) 2008-10-03 2015-06-09 Mirabilis Medica, Inc. System for treating a volume of tissue with high intensity focused ultrasound
CA2739425A1 (en) * 2008-10-03 2010-04-08 Mirabilis Medica, Inc. Method and apparatus for treating tissues with hifu
US20110208055A1 (en) * 2008-11-04 2011-08-25 Koninklijke Philips Electronics N.V. Method and system for ultrasound therapy
US8425424B2 (en) 2008-11-19 2013-04-23 Inightee Ltd. Closed-loop clot lysis
US20100179425A1 (en) * 2009-01-13 2010-07-15 Eyal Zadicario Systems and methods for controlling ultrasound energy transmitted through non-uniform tissue and cooling of same
US8606366B2 (en) 2009-02-18 2013-12-10 Syneron Medical Ltd. Skin treatment apparatus for personal use and method for using same
EP2730313A1 (en) 2009-02-25 2014-05-14 Syneron Medical Ltd. Electrical skin rejuvenation
US9108037B2 (en) * 2009-03-09 2015-08-18 St. Jude Medical, Atrial Fibrillation Division, Inc. Apparatus and method for tissue ablation with near-field cooling
US8617073B2 (en) 2009-04-17 2013-12-31 Insightec Ltd. Focusing ultrasound into the brain through the skull by utilizing both longitudinal and shear waves
US9623266B2 (en) 2009-08-04 2017-04-18 Insightec Ltd. Estimation of alignment parameters in magnetic-resonance-guided ultrasound focusing
US9289154B2 (en) 2009-08-19 2016-03-22 Insightec Ltd. Techniques for temperature measurement and corrections in long-term magnetic resonance thermometry
US9177543B2 (en) 2009-08-26 2015-11-03 Insightec Ltd. Asymmetric ultrasound phased-array transducer for dynamic beam steering to ablate tissues in MRI
EP2489034B1 (en) 2009-10-14 2016-11-30 Insightec Ltd. Mapping ultrasound transducers
JP6042723B2 (en) * 2009-10-30 2016-12-14 コナ メディカル, インコーポレイテッド Method and apparatus for non-invasive treatment of hypertension by ultrasonic renal nerve removal
US8368401B2 (en) 2009-11-10 2013-02-05 Insightec Ltd. Techniques for correcting measurement artifacts in magnetic resonance thermometry
US8715186B2 (en) 2009-11-24 2014-05-06 Guided Therapy Systems, Llc Methods and systems for generating thermal bubbles for improved ultrasound imaging and therapy
BR112012012437A2 (en) 2009-12-06 2017-12-12 Syneron Medical Ltd method and apparatus for personal skin care
WO2011080664A1 (en) 2009-12-28 2011-07-07 Koninklijke Philips Electronics N.V. Therapeutic apparatus
CA2800238C (en) 2010-03-09 2018-07-10 Profound Medical Inc. Ultrasonic therapy applicator
US9566455B2 (en) * 2010-03-09 2017-02-14 Profound Medical Inc. Fluid circuits for temperature control in a thermal therapy system
US11027154B2 (en) 2010-03-09 2021-06-08 Profound Medical Inc. Ultrasonic therapy applicator and method of determining position of ultrasonic transducers
US9707413B2 (en) 2010-03-09 2017-07-18 Profound Medical Inc. Controllable rotating ultrasound therapy applicator
WO2011115664A2 (en) * 2010-03-14 2011-09-22 Profound Medical Inc. Mri-compatible motor and positioning system
EP2560569B1 (en) * 2010-04-22 2020-10-21 Precise Light Surgical, Inc. Flash vaporization surgical systems
US8932237B2 (en) 2010-04-28 2015-01-13 Insightec, Ltd. Efficient ultrasound focusing
US9852727B2 (en) 2010-04-28 2017-12-26 Insightec, Ltd. Multi-segment ultrasound transducers
US9504446B2 (en) 2010-08-02 2016-11-29 Guided Therapy Systems, Llc Systems and methods for coupling an ultrasound source to tissue
EP2600937B8 (en) 2010-08-02 2024-03-06 Guided Therapy Systems, L.L.C. Systems for treating acute and/or chronic injuries in soft tissue
EP2423700A1 (en) * 2010-08-30 2012-02-29 Koninklijke Philips Electronics N.V. Apparatus, computer-implemented method, and computer program product for calculating temperature in accordance with MRI transverse relaxometry data
US8857438B2 (en) 2010-11-08 2014-10-14 Ulthera, Inc. Devices and methods for acoustic shielding
US9079011B2 (en) * 2011-01-03 2015-07-14 Wisconsin Alumni Research Foundation Microwave hyperthermia treatment system
US20120191020A1 (en) * 2011-01-25 2012-07-26 Shuki Vitek Uniform thermal treatment of tissue interfaces
KR101644011B1 (en) * 2011-02-01 2016-08-01 주식회사 하이로닉 High Intensity Focused Ultrasonic Medical Instrument with Dual Transducers
CN102670298A (en) * 2011-03-18 2012-09-19 中国科学院理化技术研究所 Broad spectrum type tumor thermal therapy device
US9956429B2 (en) * 2011-03-28 2018-05-01 Varian Medical Systems International Ag Method and system for automated evaluation of multiple portal dose images in radiation therapy
US8858471B2 (en) 2011-07-10 2014-10-14 Guided Therapy Systems, Llc Methods and systems for ultrasound treatment
KR20190080967A (en) 2011-07-11 2019-07-08 가이디드 테라피 시스템스, 엘.엘.씨. Systems and methods for coupling an ultrasound source to tissue
KR20130009138A (en) * 2011-07-14 2013-01-23 삼성전자주식회사 Focused ultrasound therapy apparatus and focal point controlling method thereof
KR20130020421A (en) * 2011-08-19 2013-02-27 삼성전자주식회사 Method and system for monitoring temperature of treatment site using ultrasound, system for treatment and diagnosis using ultrasound
JP6295395B2 (en) * 2011-08-30 2018-03-20 プロファウンド メディカル インク Real-time control of high-intensity focused ultrasound using magnetic resonance imaging
US11116405B2 (en) * 2012-04-12 2021-09-14 Profound Medical Inc. High-intensity focused ultrasound for heating a target zone larger than the electronic focusing zone
US9263663B2 (en) 2012-04-13 2016-02-16 Ardent Sound, Inc. Method of making thick film transducer arrays
EP2676702A1 (en) * 2012-06-21 2013-12-25 Koninklijke Philips N.V. Improved high intensity focused ultrasound targeting
US9901398B2 (en) * 2012-06-29 2018-02-27 Covidien Lp Microwave antenna probes
KR20140008103A (en) * 2012-07-10 2014-01-21 삼성전자주식회사 A method and apparatus for generating a treatment plan to be provided to a focused ultrasound therapy apparatus
US9510802B2 (en) 2012-09-21 2016-12-06 Guided Therapy Systems, Llc Reflective ultrasound technology for dermatological treatments
CN104684616B (en) * 2012-10-01 2019-01-18 博放医疗有限公司 Reduce the heating in the overlapping near-field region of high intensity focused ultrasound
EP2749318A1 (en) * 2012-12-28 2014-07-02 Theraclion SA Image-guided therapeutic apparatus and method of preparation of an image-guided therapeutic apparatus for treatment of tissue
CN204637350U (en) 2013-03-08 2015-09-16 奥赛拉公司 Aesthstic imaging and processing system, multifocal processing system and perform the system of aesthetic procedure
WO2014146022A2 (en) 2013-03-15 2014-09-18 Guided Therapy Systems Llc Ultrasound treatment device and methods of use
JP6266749B2 (en) * 2013-04-05 2018-01-24 プロファウンド メディカル インク Determination of the energy deposition zone of a catheter equipped with an ultrasonic array
EP3035883B1 (en) * 2013-08-23 2017-03-29 Koninklijke Philips N.V. Medical instrument with multiple displays for controlling a treatment system
CN103783157A (en) * 2014-01-02 2014-05-14 陆开云 Balsam pear-corn beverage for slimming
BR112016023889B1 (en) 2014-04-18 2023-02-07 Ulthera, Inc ULTRASOUND TRANSDUCTION SYSTEM FOR LINEAR FOCUSING ULTRASOUND
US10420608B2 (en) * 2014-05-20 2019-09-24 Verily Life Sciences Llc System for laser ablation surgery
CN106999233B (en) * 2014-12-31 2019-09-10 成功大学 Heating system
WO2016156036A1 (en) * 2015-03-27 2016-10-06 Koninklijke Philips N.V. Medical instrument for sonicating a set of target volumes
US10607738B2 (en) 2015-05-15 2020-03-31 University Health Network System and method for minimally invasive thermal ablation treatment planning
PT3405294T (en) 2016-01-18 2023-03-03 Ulthera Inc Compact ultrasound device having annular ultrasound array peripherally electrically connected to flexible printed circuit board and method of assembly thereof
KR20230149878A (en) 2016-08-16 2023-10-27 얼테라, 인크 Systems and methods for cosmetic ultrasound treatment of skin
CN107789752B (en) * 2016-08-31 2019-05-31 重庆海扶医疗科技股份有限公司 Focusing ultrasonic therapeutic system
WO2018175322A1 (en) 2017-03-20 2018-09-27 Precise Light Surgical, Inc. Soft tissue selective ablation surgical systems
EP3628251A1 (en) * 2018-09-28 2020-04-01 Koninklijke Philips N.V. Ablation therapy planning system
US20220313358A1 (en) * 2021-04-01 2022-10-06 Worcester Polytechnic Institute Estimating optical properties of surgical tissue
WO2023039394A1 (en) * 2021-09-08 2023-03-16 Lastarria Emilio Laser ablation surgery system with safety control of temperature and pressure at surgical site and method of use
CN114028741A (en) * 2021-11-16 2022-02-11 上海吾魅科技有限公司 Probe combining high-intensity focused ultrasound and superficial imaging ultrasound

Citations (233)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2795709A (en) 1953-12-21 1957-06-11 Bendix Aviat Corp Electroplated ceramic rings
US3142035A (en) 1960-02-04 1964-07-21 Harris Transducer Corp Ring-shaped transducer
US3942150A (en) 1974-08-12 1976-03-02 The United States Of America As Represented By The Secretary Of The Navy Correction of spatial non-uniformities in sonar, radar, and holographic acoustic imaging systems
US3974475A (en) 1971-10-07 1976-08-10 Hoffmann-La Roche Inc. Method of and apparatus for focusing ultrasonic waves in a focal line
US3992693A (en) 1972-12-04 1976-11-16 The Bendix Corporation Underwater transducer and projector therefor
US4000493A (en) 1971-04-12 1976-12-28 Eastman Kodak Company Acoustooptic scanner apparatus and method
US4074564A (en) 1974-04-25 1978-02-21 Varian Associates, Inc. Reconstruction system and method for ultrasonic imaging
US4206653A (en) 1975-10-02 1980-06-10 E M I Limited Ultrasonic apparatus
EP0031614A1 (en) 1979-12-17 1981-07-08 North American Philips Corporation Curved array of sequenced ultrasound transducers
US4339952A (en) 1979-04-26 1982-07-20 Ontario Cancer Institute Cylindrical transducer ultrasonic scanner
US4441486A (en) * 1981-10-27 1984-04-10 Board Of Trustees Of Leland Stanford Jr. University Hyperthermia system
US4454597A (en) 1982-05-03 1984-06-12 The United States Of America As Represented By The Secretary Of The Navy Conformal array compensating beamformer
US4478083A (en) 1982-06-30 1984-10-23 Siemens Aktiengesellschaft Plane reconstruction ultrasound tomography device
US4505156A (en) 1983-06-21 1985-03-19 Sound Products Company L.P. Method and apparatus for switching multi-element transducer arrays
US4526168A (en) 1981-05-14 1985-07-02 Siemens Aktiengesellschaft Apparatus for destroying calculi in body cavities
US4537074A (en) 1983-09-12 1985-08-27 Technicare Corporation Annular array ultrasonic transducers
US4549533A (en) 1984-01-30 1985-10-29 University Of Illinois Apparatus and method for generating and directing ultrasound
US4554925A (en) 1982-07-07 1985-11-26 Picker International, Ltd. Nuclear magnetic resonance imaging method
US4586512A (en) * 1981-06-26 1986-05-06 Thomson-Csf Device for localized heating of biological tissues
US4636964A (en) 1982-05-04 1987-01-13 Krautkramer-Branson, Inc. Method and system for generating and adjusting a predetermined quantity of mutually independent direct current voltages
US4662222A (en) 1984-12-21 1987-05-05 Johnson Steven A Apparatus and method for acoustic imaging using inverse scattering techniques
US4858597A (en) 1983-06-01 1989-08-22 Richard Wolf Gmbh Piezoelectric transducer for the destruction of concretions within an animal body
US4865042A (en) 1985-08-16 1989-09-12 Hitachi, Ltd. Ultrasonic irradiation system
US4888746A (en) 1987-09-24 1989-12-19 Richard Wolf Gmbh Focussing ultrasound transducer
US4889122A (en) 1985-11-29 1989-12-26 Aberdeen University Divergent ultrasound arrays
US4893284A (en) 1988-05-27 1990-01-09 General Electric Company Calibration of phased array ultrasound probe
US4893624A (en) 1988-06-21 1990-01-16 Massachusetts Institute Of Technology Diffuse focus ultrasound hyperthermia system
US4937767A (en) 1986-12-24 1990-06-26 Hewlett-Packard Company Method and apparatus for adjusting the intensity profile of an ultrasound beam
WO1991000059A1 (en) 1989-07-03 1991-01-10 Institut National De La Sante Et De La Recherche Medicale Equipment for obtaining medical, pharmacological or other data by nuclear and echographic magnetic resonance
US5209221A (en) 1988-03-01 1993-05-11 Richard Wolf Gmbh Ultrasonic treatment of pathological tissue
US5211160A (en) 1988-09-14 1993-05-18 Interpore Orthopaedics, Inc. Ultrasonic orthopedic treatment head and body-mounting means therefor
US5247935A (en) 1992-03-19 1993-09-28 General Electric Company Magnetic resonance guided focussed ultrasound surgery
JPH05300910A (en) 1992-02-28 1993-11-16 Toshiba Corp Ultrasonic medical treatment system
US5271400A (en) 1992-04-01 1993-12-21 General Electric Company Tracking system to monitor the position and orientation of a device using magnetic resonance detection of a sample contained within the device
US5275165A (en) 1992-11-06 1994-01-04 General Electric Company Magnetic resonance guided ultrasound therapy system with inclined track to move transducers in a small vertical space
US5291890A (en) 1991-08-29 1994-03-08 General Electric Company Magnetic resonance surgery using heat waves produced with focussed ultrasound
US5307816A (en) 1991-08-21 1994-05-03 Kabushiki Kaisha Toshiba Thrombus resolving treatment apparatus
US5307812A (en) 1993-03-26 1994-05-03 General Electric Company Heat surgery system monitored by real-time magnetic resonance profiling
US5318025A (en) 1992-04-01 1994-06-07 General Electric Company Tracking system to monitor the position and orientation of a device using multiplexed magnetic resonance detection
US5329930A (en) 1993-10-12 1994-07-19 General Electric Company Phased array sector scanner with multiplexed acoustic transducer elements
US5368031A (en) 1993-08-29 1994-11-29 General Electric Company Magnetic resonance surgery using heat waves produced with a laser fiber
US5368032A (en) 1993-11-09 1994-11-29 General Electric Company Manually positioned focussed energy system guided by medical imaging
US5379642A (en) 1993-07-19 1995-01-10 Diasonics Ultrasound, Inc. Method and apparatus for performing imaging
US5391140A (en) 1993-01-29 1995-02-21 Siemens Aktiengesellschaft Therapy apparatus for locating and treating a zone in the body of a life form with acoustic waves
US5413550A (en) 1993-07-21 1995-05-09 Pti, Inc. Ultrasound therapy system with automatic dose control
US5435304A (en) * 1992-04-24 1995-07-25 Siemens Aktiengesellschaft Method and apparatus for therapeutic treatment with focussed acoustic waves switchable between a locating mode and a therapy mode
US5435312A (en) 1991-05-31 1995-07-25 Spivey; Brett A. Acoustic imaging device
US5443068A (en) 1994-09-26 1995-08-22 General Electric Company Mechanical positioner for magnetic resonance guided ultrasound therapy
US5474071A (en) 1991-03-05 1995-12-12 Technomed Medical Systems Therapeutic endo-rectal probe and apparatus constituting an application thereof for destroying cancer tissue, in particular of the prostate, and preferably in combination with an imaging endo-cavitary-probe
US5490840A (en) 1994-09-26 1996-02-13 General Electric Company Targeted thermal release of drug-polymer conjugates
US5501655A (en) * 1992-03-31 1996-03-26 Massachusetts Institute Of Technology Apparatus and method for acoustic heat generation and hyperthermia
US5507790A (en) 1994-03-21 1996-04-16 Weiss; William V. Method of non-invasive reduction of human site-specific subcutaneous fat tissue deposits by accelerated lipolysis metabolism
US5520188A (en) 1994-11-02 1996-05-28 Focus Surgery Inc. Annular array transducer
US5526814A (en) 1993-11-09 1996-06-18 General Electric Company Automatically positioned focussed energy system guided by medical imaging
US5526815A (en) * 1993-01-29 1996-06-18 Siemens Aktiengesellschat Therapy apparatus for locating and treating a zone located in the body of a life form with acoustic waves
US5549638A (en) 1994-05-17 1996-08-27 Burdette; Everette C. Ultrasound device for use in a thermotherapy apparatus
US5553618A (en) 1993-03-12 1996-09-10 Kabushiki Kaisha Toshiba Method and apparatus for ultrasound medical treatment
US5573497A (en) 1994-11-30 1996-11-12 Technomed Medical Systems And Institut National High-intensity ultrasound therapy method and apparatus with controlled cavitation effect and reduced side lobes
US5582578A (en) 1995-08-01 1996-12-10 Duke University Method for the comminution of concretions
US5590657A (en) 1995-11-06 1997-01-07 The Regents Of The University Of Michigan Phased array ultrasound system and method for cardiac ablation
US5590653A (en) 1993-03-10 1997-01-07 Kabushiki Kaisha Toshiba Ultrasonic wave medical treatment apparatus suitable for use under guidance of magnetic resonance imaging
US5601526A (en) 1991-12-20 1997-02-11 Technomed Medical Systems Ultrasound therapy apparatus delivering ultrasound waves having thermal and cavitation effects
US5605154A (en) 1995-06-06 1997-02-25 Duke University Two-dimensional phase correction using a deformable ultrasonic transducer array
US5617371A (en) 1995-02-08 1997-04-01 Diagnostic/Retrieval Systems, Inc. Method and apparatus for accurately determing the location of signal transducers in a passive sonar or other transducer array system
US5617857A (en) 1995-06-06 1997-04-08 Image Guided Technologies, Inc. Imaging system having interactive medical instruments and methods
US5643179A (en) 1993-12-28 1997-07-01 Kabushiki Kaisha Toshiba Method and apparatus for ultrasonic medical treatment with optimum ultrasonic irradiation control
US5662170A (en) 1994-11-22 1997-09-02 Baker Hughes Incorporated Method of drilling and completing wells
US5665054A (en) 1994-01-27 1997-09-09 Technomed Medical Systems S.A. Control method for hyperthermia treatment apparatus using ultrasound
US5676673A (en) 1994-09-15 1997-10-14 Visualization Technology, Inc. Position tracking and imaging system with error detection for use in medical applications
US5687729A (en) 1994-06-22 1997-11-18 Siemens Aktiengesellschaft Source of therapeutic acoustic waves introducible into the body of a patient
US5694936A (en) 1994-09-17 1997-12-09 Kabushiki Kaisha Toshiba Ultrasonic apparatus for thermotherapy with variable frequency for suppressing cavitation
US5711300A (en) 1995-08-16 1998-01-27 General Electric Company Real time in vivo measurement of temperature changes with NMR imaging
US5739625A (en) 1994-05-09 1998-04-14 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Island Segmented ring transducers
US5752515A (en) 1996-08-21 1998-05-19 Brigham & Women's Hospital Methods and apparatus for image-guided ultrasound delivery of compounds through the blood-brain barrier
US5759162A (en) 1992-03-10 1998-06-02 Siemens Aktiengesellschaft Method and apparatus for ultrasound tissue therapy
US5762616A (en) 1996-03-15 1998-06-09 Exogen, Inc. Apparatus for ultrasonic treatment of sites corresponding to the torso
US5769790A (en) 1996-10-25 1998-06-23 General Electric Company Focused ultrasound surgery system guided by ultrasound imaging
US5810008A (en) 1996-12-03 1998-09-22 Isg Technologies Inc. Apparatus and method for visualizing ultrasonic images
US5817036A (en) 1997-02-20 1998-10-06 General Electric Company System and method for treatment of a prostate with a phase fresnel probe
US5823962A (en) * 1996-09-02 1998-10-20 Siemens Aktiengesellschaft Ultrasound transducer for diagnostic and therapeutic use
EP0875203A2 (en) 1997-04-03 1998-11-04 SonoSight, Inc. Ultrasonic array transducer for a hand held diagnostic instrument
WO1998052465A1 (en) 1997-05-23 1998-11-26 Transurgical, Inc. Mri-guided therapeutic unit and methods
US5873845A (en) 1997-03-17 1999-02-23 General Electric Company Ultrasound transducer with focused ultrasound refraction plate
US5938600A (en) 1995-12-14 1999-08-17 U.S. Philips Corporation Method and device for heating by means of ultrasound
US5938608A (en) 1995-03-03 1999-08-17 Siemens Aktiengesellschaft Therapy apparatus for carrying out treatment with focused ultrasound
US5947900A (en) 1998-04-13 1999-09-07 General Electric Company Dynamic scan plane tracking using MR position monitoring
US5984881A (en) 1995-03-31 1999-11-16 Kabushiki Kaisha Toshiba Ultrasound therapeutic apparatus using a therapeutic ultrasonic wave source and an ultrasonic probe
JPH11313833A (en) 1992-02-28 1999-11-16 Toshiba Corp Ultrasonic therapeutic device
US6004269A (en) 1993-07-01 1999-12-21 Boston Scientific Corporation Catheters for imaging, sensing electrical potentials, and ablating tissue
US6023636A (en) 1997-06-25 2000-02-08 Siemens Aktiengesellschaft Magnetic resonance apparatus and method for determining the location of a positionable object in a subject
US6042556A (en) 1998-09-04 2000-03-28 University Of Washington Method for determining phase advancement of transducer elements in high intensity focused ultrasound
WO2000031614A1 (en) 1998-11-25 2000-06-02 Flashpoint Technology, Inc. Digital image capture devices and methods and systems associated therewith
US6071239A (en) 1997-10-27 2000-06-06 Cribbs; Robert W. Method and apparatus for lipolytic therapy using ultrasound energy
US6113558A (en) 1997-09-29 2000-09-05 Angiosonics Inc. Pulsed mode lysis method
US6113559A (en) 1997-12-29 2000-09-05 Klopotek; Peter J. Method and apparatus for therapeutic treatment of skin with ultrasound
US6128958A (en) 1997-09-11 2000-10-10 The Regents Of The University Of Michigan Phased array system architecture
DE4345308C2 (en) 1992-07-15 2001-02-01 Fukuda Denshi Kk Medical ultrasonic diagnosis system
US6193659B1 (en) 1997-07-15 2001-02-27 Acuson Corporation Medical ultrasonic diagnostic imaging method and apparatus
US6242915B1 (en) 1999-08-27 2001-06-05 General Electric Company Field-frequency lock system for magnetic resonance system
US6246896B1 (en) 1998-11-24 2001-06-12 General Electric Company MRI guided ablation system
US6263230B1 (en) 1997-05-08 2001-07-17 Lucent Medical Systems, Inc. System and method to determine the location and orientation of an indwelling medical device
WO2001058337A2 (en) 2000-02-09 2001-08-16 Spencer Technologies, Inc. Method and apparatus combining diagnostic ultrasound with therapeutic ultrasound to enhance thrombolysis
US6289233B1 (en) 1998-11-25 2001-09-11 General Electric Company High speed tracking of interventional devices using an MRI system
EP1132054A1 (en) 1998-10-26 2001-09-12 Hitachi, Ltd. Ultrasonic medical treating device
WO2001066189A1 (en) 2000-03-09 2001-09-13 Transurgical, Inc. Hifu application with feedback control using bubble detection
FR2806611A1 (en) 2000-03-22 2001-09-28 Hossein Kafai Medical ultrasonic imaging device for examination of jaw region uses ultrasonic probes arranged on either side of face
US20010031922A1 (en) 1999-12-23 2001-10-18 Therus Corporation Ultrasound transducers for imaging and therapy
US6309355B1 (en) 1998-12-22 2001-10-30 The Regents Of The University Of Michigan Method and assembly for performing ultrasound surgery using cavitation
WO2001080709A2 (en) 2000-04-21 2001-11-01 Txsonics Ltd. Systems and methods for creating longer necrosed volumes using a phased array focused ultrasound system
US6317619B1 (en) 1999-07-29 2001-11-13 U.S. Philips Corporation Apparatus, methods, and devices for magnetic resonance imaging controlled by the position of a moveable RF coil
US6322527B1 (en) 1997-04-18 2001-11-27 Exogen, Inc. Apparatus for ultrasonic bone treatment
WO2001043640A3 (en) 1999-12-15 2001-12-13 Koninkl Philips Electronics Nv Diagnostic imaging system with ultrasound probe
US6334846B1 (en) 1995-03-31 2002-01-01 Kabushiki Kaisha Toshiba Ultrasound therapeutic apparatus
US20020035779A1 (en) 2000-06-09 2002-03-28 Robert Krieg Method for three-dimensionally correcting distortions and magnetic resonance apparatus for implementing the method
US6392330B1 (en) 2000-06-05 2002-05-21 Pegasus Technologies Ltd. Cylindrical ultrasound receivers and transceivers formed from piezoelectric film
US6397094B1 (en) 1998-01-09 2002-05-28 Koninklijke Philips Electronics N.V. MR method utilizing microcoils situated in the examination zone
US20020082589A1 (en) 2000-12-27 2002-06-27 Insightec - Image Guided Treatement Ltd. Systems and methods for ultrasound assisted lipolysis
US6419648B1 (en) 2000-04-21 2002-07-16 Insightec-Txsonics Ltd. Systems and methods for reducing secondary hot spots in a phased array focused ultrasound system
US6424597B1 (en) 1998-11-27 2002-07-23 Commissariat A L'energie Atomique Multielements ultrasonic contact transducer
US6425867B1 (en) 1998-09-18 2002-07-30 University Of Washington Noise-free real time ultrasonic imaging of a treatment site undergoing high intensity focused ultrasound therapy
WO2002058791A1 (en) 2000-12-15 2002-08-01 The Brigham And Women's Hospital, Inc. Method and system for calculating phase and amplitude corrections in ultrasound therapy
US6428532B1 (en) 1998-12-30 2002-08-06 The General Hospital Corporation Selective tissue targeting by difference frequency of two wavelengths
DE10102317A1 (en) 2001-01-19 2002-08-14 Hmt Ag Method and device for applying pressure waves to the body of a living being
US6461314B1 (en) 1999-02-02 2002-10-08 Transurgical, Inc. Intrabody hifu applicator
US6475150B2 (en) 2000-12-01 2002-11-05 The Regents Of The University Of California System and method for ultrasonic tomography
US6478739B1 (en) 2001-05-11 2002-11-12 The Procter & Gamble Company Ultrasonic breast examination system
US20020188229A1 (en) 1997-02-06 2002-12-12 Ryaby John P. Method and apparatus for cartilage growth stimulation
US6506171B1 (en) 2000-07-27 2003-01-14 Insightec-Txsonics, Ltd System and methods for controlling distribution of acoustic energy around a focal point using a focused ultrasound system
US6506154B1 (en) 2000-11-28 2003-01-14 Insightec-Txsonics, Ltd. Systems and methods for controlling a phased array focused ultrasound system
US6522142B1 (en) 2001-12-14 2003-02-18 Insightec-Txsonics Ltd. MRI-guided temperature mapping of tissue undergoing thermal treatment
WO2003013654A1 (en) 2001-08-09 2003-02-20 Exogen, Inc. Method and means for controlling acoustic modes in tissue healing applications
US20030060820A1 (en) 1997-07-08 2003-03-27 Maguire Mark A. Tissue ablation device assembly and method for electrically isolating a pulmonary vein ostium from an atrial wall
US6543272B1 (en) 2000-04-21 2003-04-08 Insightec-Txsonics Ltd. Systems and methods for testing and calibrating a focused ultrasound transducer array
US6554826B1 (en) 2000-04-21 2003-04-29 Txsonics-Ltd Electro-dynamic phased array lens for controlling acoustic wave propagation
US6559644B2 (en) 2001-05-30 2003-05-06 Insightec - Txsonics Ltd. MRI-based temperature mapping with error compensation
US6566878B1 (en) 1999-09-09 2003-05-20 Hitachi Medical Corporation Magnetic resonance imaging device and method therefor
US6582381B1 (en) 2000-07-31 2003-06-24 Txsonics Ltd. Mechanical positioner for MRI guided ultrasound therapy system
US6599256B1 (en) 1999-09-10 2003-07-29 Transurgical, Inc. Occlusion of tubular anatomical structures by energy application
WO2003070105A1 (en) 2002-02-20 2003-08-28 Liposonix, Inc. Ultrasonic treatment and imaging of adipose tissue
US6613005B1 (en) 2000-11-28 2003-09-02 Insightec-Txsonics, Ltd. Systems and methods for steering a focused ultrasound array
US6618608B1 (en) 1999-11-30 2003-09-09 Txsonics, Ltd. Thermal imaging of fat and muscle using a simultaneous phase and magnitude double echo sequence
US6618620B1 (en) 2000-11-28 2003-09-09 Txsonics Ltd. Apparatus for controlling thermal dosing in an thermal treatment system
US6626854B2 (en) 2000-12-27 2003-09-30 Insightec - Txsonics Ltd. Systems and methods for ultrasound assisted lipolysis
US6626855B1 (en) 1999-11-26 2003-09-30 Therus Corpoation Controlled high efficiency lesion formation using high intensity ultrasound
US20030187371A1 (en) 2002-03-27 2003-10-02 Insightec-Txsonics Ltd. Systems and methods for enhanced focused ultrasound ablation using microbubbles
US6629929B1 (en) 2002-11-08 2003-10-07 Koninklijke Philips Electronics N.V. Method and apparatus for automatically setting the transmit aperture and apodization of an ultrasound transducer array
US6652461B1 (en) 1999-04-15 2003-11-25 F.R.A.Y Project Ltd. Ultrasound device for three-dimensional imaging of internal structure of a body part
WO2003098232A2 (en) 2002-05-17 2003-11-27 Case Western Reserve University Chemical shift markers for improved wireless fiducial marker tracking
US6666833B1 (en) 2000-11-28 2003-12-23 Insightec-Txsonics Ltd Systems and methods for focussing an acoustic energy beam transmitted through non-uniform tissue medium
US6676601B1 (en) 1999-05-26 2004-01-13 Technomed Medical Systems, S.A. Apparatus and method for location and treatment using ultrasound
US6679855B2 (en) 2000-11-07 2004-01-20 Gerald Horn Method and apparatus for the correction of presbyopia using high intensity focused ultrasound
US20040030251A1 (en) 2002-05-10 2004-02-12 Ebbini Emad S. Ultrasound imaging system and method using non-linear post-beamforming filter
US6705994B2 (en) 2002-07-08 2004-03-16 Insightec - Image Guided Treatment Ltd Tissue inhomogeneity correction in ultrasound imaging
US20040068186A1 (en) 2001-01-22 2004-04-08 Kazunari Ishida Ultrasonic therapeutic probe and ultrasonic device
US6735461B2 (en) 2001-06-19 2004-05-11 Insightec-Txsonics Ltd Focused ultrasound system with MRI synchronization
US6733450B1 (en) 2000-07-27 2004-05-11 Texas Systems, Board Of Regents Therapeutic methods and apparatus for use of sonication to enhance perfusion of tissue
US20040122323A1 (en) 2002-12-23 2004-06-24 Insightec-Txsonics Ltd Tissue aberration corrections in ultrasound therapy
US6761691B2 (en) 2000-07-21 2004-07-13 Fuji Photo Film Co., Ltd. Image forming method used in ultrasonic diagnosis, ultrasonic diagnostic apparatus, signal processing apparatus, and recording medium for recording signal processing program
US20040147919A1 (en) 1999-06-25 2004-07-29 Scimed Life Systems, Inc. Method and system for heating solid tissue
US6770039B2 (en) 2001-11-09 2004-08-03 Duke University Method to reduce tissue injury in shock wave lithotripsy
US6770031B2 (en) 2000-12-15 2004-08-03 Brigham And Women's Hospital, Inc. Ultrasound therapy
US6788619B2 (en) 2001-09-07 2004-09-07 Shell Oil Company Concentrating seismic energy in a selected target point in an underground formation
US6790180B2 (en) 2001-12-03 2004-09-14 Insightec-Txsonics Ltd. Apparatus, systems, and methods for measuring power output of an ultrasound transducer
US20040210134A1 (en) 2003-04-17 2004-10-21 Kullervo Hynynen Shear mode therapeutic ultrasound
WO2004093686A1 (en) 2003-04-17 2004-11-04 The Brigham & Women's Hospital, Inc. Shear mode diagnostic ultrasound
US20040236253A1 (en) 2003-05-22 2004-11-25 Insightec-Image Guided Treatment Ltd. Acoustic beam forming in phased arrays including large numbers of transducer elements
US6824516B2 (en) 2002-03-11 2004-11-30 Medsci Technologies, Inc. System for examining, mapping, diagnosing, and treating diseases of the prostate
US20040267126A1 (en) 2003-06-25 2004-12-30 Aloka Co., Ltd. Ultrasound diagnosis apparatus
US20050033201A1 (en) 2003-08-07 2005-02-10 Olympus Corporation Ultrasonic surgical system
US20050131301A1 (en) 2003-12-12 2005-06-16 Michael Peszynski Ultrasound probe receptacle
US20050203444A1 (en) 2002-10-25 2005-09-15 Compex Medical S.A. Ultrasound therapeutic device
US20050240126A1 (en) 1999-09-17 2005-10-27 University Of Washington Ultrasound guided high intensity focused ultrasound treatment of nerves
US6961606B2 (en) 2001-10-19 2005-11-01 Koninklijke Philips Electronics N.V. Multimodality medical imaging system and method with separable detector devices
US20050251046A1 (en) 2004-03-29 2005-11-10 Yuko Yamamoto Probe array producing method
JP2002505596A5 (en) 1998-05-22 2005-12-08
WO2005058029A3 (en) 2003-12-17 2005-12-22 Mentor Graphics Corp Mask creation with hierarchy management using cover cells
WO2006025001A1 (en) 2004-09-01 2006-03-09 Koninklijke Philips Electronics, N.V. Magnetic resonance marker based position and orientation probe
US20060052706A1 (en) 2004-08-20 2006-03-09 Kullervo Hynynen Phased array ultrasound for cardiac ablation
US20060052661A1 (en) 2003-01-23 2006-03-09 Ramot At Tel Aviv University Ltd. Minimally invasive control surgical system with feedback
US20060052701A1 (en) 1998-09-18 2006-03-09 University Of Washington Treatment of unwanted tissue by the selective destruction of vasculature providing nutrients to the tissue
US20060058678A1 (en) 2004-08-26 2006-03-16 Insightec - Image Guided Treatment Ltd. Focused ultrasound system for surrounding a body tissue mass
US20060106300A1 (en) 2003-04-24 2006-05-18 Universiteit Utrecht Holding B.V. Selective MR imaging of magnetic susceptibility deviations
US7077820B1 (en) 2002-10-21 2006-07-18 Advanced Medical Optics, Inc. Enhanced microburst ultrasonic power delivery system and method
US20060173385A1 (en) 2003-06-04 2006-08-03 Lars Lidgren Ultrasound probe having a central opening
US20060184069A1 (en) 2005-02-02 2006-08-17 Vaitekunas Jeffrey J Focused ultrasound for pain reduction
US7094205B2 (en) 2001-04-06 2006-08-22 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California High-resolution 3D ultrasonic transmission imaging
WO2006087649A1 (en) 2005-02-17 2006-08-24 Koninklijke Philips Electronics, N.V. Method and apparatus for the visualization of the focus generated using focused ultrasound
US20060206105A1 (en) 2005-03-09 2006-09-14 Rajiv Chopra Treatment of diseased tissue using controlled ultrasonic heating
US20060229594A1 (en) 2000-01-19 2006-10-12 Medtronic, Inc. Method for guiding a medical device
US7128711B2 (en) 2002-03-25 2006-10-31 Insightec, Ltd. Positioning systems and methods for guided ultrasound therapy systems
WO2006119572A1 (en) 2005-05-12 2006-11-16 Compumedics Medical Innovation Pty Ltd Ultrasound diagnosis and treatment apparatus
US7155271B2 (en) 1998-11-04 2006-12-26 Johns Hopkins University School Of Medicine System and method for magnetic-resonance-guided electrophysiologic and ablation procedures
US20070016039A1 (en) 2005-06-21 2007-01-18 Insightec-Image Guided Treatment Ltd. Controlled, non-linear focused ultrasound treatment
US7175596B2 (en) 2001-10-29 2007-02-13 Insightec-Txsonics Ltd System and method for sensing and locating disturbances in an energy path of a focused ultrasound system
US20070055140A1 (en) 2003-07-11 2007-03-08 Kagayaki Kuroda Self-referencing/body motion tracking non-invasive internal temperature distribution measurement method and apparatus using magnetic resonance tomographic imaging technique
US20070066897A1 (en) 2005-07-13 2007-03-22 Sekins K M Systems and methods for performing acoustic hemostasis of deep bleeding trauma in limbs
US20070073135A1 (en) 2005-09-13 2007-03-29 Warren Lee Integrated ultrasound imaging and ablation probe
EP1774920A1 (en) 2004-06-21 2007-04-18 Hiroshi Furuhata Ultrasonic brain infarction treating device
US20070098232A1 (en) 2005-09-14 2007-05-03 University Of Washington Using optical scattering to measure properties of ultrasound contrast agent shells
WO2006018837A3 (en) 2004-08-17 2007-05-18 Technion Res & Dev Foundation Ultrasonic image-guided tissue-damaging procedure
EP1790384A1 (en) 2005-11-23 2007-05-30 Siemens Medical Solutions USA, Inc. Contrast agent augmented ultrasound therapy system with ultrasound imaging guidance for thrombus treatment
WO2007073551A1 (en) 2005-12-22 2007-06-28 Boston Scientific Scimed, Inc. Device and method for determining the location of a vascular opening prior to application of hifu energy to seal the opening
US20070167781A1 (en) 2005-11-23 2007-07-19 Insightec Ltd. Hierarchical Switching in Ultra-High Density Ultrasound Array
WO2007093998A1 (en) 2006-02-16 2007-08-23 Syneron Medical Ltd. Method and apparatus for treatment of adipose tissue
US20070197918A1 (en) 2003-06-02 2007-08-23 Insightec - Image Guided Treatment Ltd. Endo-cavity focused ultrasound transducer
US7264592B2 (en) 2002-06-28 2007-09-04 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Scanning devices for three-dimensional ultrasound mammography
US7264597B2 (en) 2001-10-04 2007-09-04 Institut National De La Sante Et De Lacrecherchedmedicale Device and method for producing high-pressure ultrasonic pulses
US7267650B2 (en) 2002-12-16 2007-09-11 Cardiac Pacemakers, Inc. Ultrasound directed guiding catheter system and method
US20070219470A1 (en) 2006-03-08 2007-09-20 Talish Roger J System and method for providing therapeutic treatment using a combination of ultrasound, electro-stimulation and vibrational stimulation
US20080027342A1 (en) 2006-07-28 2008-01-31 Mattias Rouw Prioritized Multicomplexor Sensing Circuit
US20080033278A1 (en) 2006-08-01 2008-02-07 Insightec Ltd. System and method for tracking medical device using magnetic resonance detection
US20080031090A1 (en) 2006-08-01 2008-02-07 Insightec, Ltd Transducer surface mapping
WO2008039449A1 (en) 2006-09-27 2008-04-03 Siemens Medical Solutions Usa, Inc. Automated contrast agent augmented ultrasound therapy for thrombus treatment
US20080082026A1 (en) 2006-04-26 2008-04-03 Rita Schmidt Focused ultrasound system with far field tail suppression
WO2008050278A1 (en) 2006-10-23 2008-05-02 Koninklijke Philips Electronics, N.V. Symmetric and preferentially steered random arrays for ultrasound therapy
US20080108900A1 (en) 2006-09-29 2008-05-08 Chih-Kung Lee Ultrasound transducer apparatus
WO2008075203A2 (en) 2006-06-21 2008-06-26 Martinswerk Gmbh Process for the production of aluminum hydroxide
US20080183077A1 (en) 2006-10-19 2008-07-31 Siemens Corporate Research, Inc. High intensity focused ultrasound path determination
US20080228081A1 (en) 2004-04-02 2008-09-18 Koninklijke Philips Electronics, N.V. Ultrasonic Intracavity Probe For 3D Imaging
WO2008119054A1 (en) 2007-03-27 2008-10-02 Abqmr, Inc. System and method for detecting labeled entities using microcoil magnetic mri
US7452357B2 (en) 2004-10-22 2008-11-18 Ethicon Endo-Surgery, Inc. System and method for planning treatment of tissue
US20080312562A1 (en) 2005-12-14 2008-12-18 Koninklijke Philips Electronics, N.V. Method and Apparatus for Guidance and Application of High Intensity Focused Ultrasound for Control of Bleeding Due to Severed Limbs
US7505808B2 (en) 2004-04-28 2009-03-17 Sunnybrook Health Sciences Centre Catheter tracking with phase information
US7511501B2 (en) 2007-05-11 2009-03-31 General Electric Company Systems and apparatus for monitoring internal temperature of a gradient coil
US20090088623A1 (en) 2007-10-01 2009-04-02 Insightec, Ltd. Motion compensated image-guided focused ultrasound therapy system
US20090096450A1 (en) 2007-10-12 2009-04-16 Joerg Roland Bo field drift correction in a temperature map generated by magnetic resonance tomography
WO2009055587A1 (en) 2007-10-23 2009-04-30 Abqmr, Inc. Microcoil magnetic resonance detectors
WO2009094554A2 (en) 2008-01-25 2009-07-30 The Regents Of The University Of Michigan Histotripsy for thrombolysis
US7603162B2 (en) 2004-01-28 2009-10-13 Siemens Aktiengesellschaft Imaging tomography apparatus with fluid-containing chambers forming out-of-balance compensating weights for a rotating part
US7652410B2 (en) 2006-08-01 2010-01-26 Insightec Ltd Ultrasound transducer with non-uniform elements
US7699780B2 (en) 2004-08-11 2010-04-20 Insightec—Image-Guided Treatment Ltd. Focused ultrasound system with adaptive anatomical aperture shaping
EP1591073A4 (en) 2003-01-31 2010-11-17 Hitachi Medical Corp Ultrasonic probe and ultrasonic device
EP1582886B1 (en) 2004-04-02 2012-08-15 Universität Zürich Magnetic resonance apparatus with magnetic field detectors

Patent Citations (265)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2795709A (en) 1953-12-21 1957-06-11 Bendix Aviat Corp Electroplated ceramic rings
US3142035A (en) 1960-02-04 1964-07-21 Harris Transducer Corp Ring-shaped transducer
US4000493A (en) 1971-04-12 1976-12-28 Eastman Kodak Company Acoustooptic scanner apparatus and method
US3974475A (en) 1971-10-07 1976-08-10 Hoffmann-La Roche Inc. Method of and apparatus for focusing ultrasonic waves in a focal line
US3992693A (en) 1972-12-04 1976-11-16 The Bendix Corporation Underwater transducer and projector therefor
US4074564A (en) 1974-04-25 1978-02-21 Varian Associates, Inc. Reconstruction system and method for ultrasonic imaging
US3942150A (en) 1974-08-12 1976-03-02 The United States Of America As Represented By The Secretary Of The Navy Correction of spatial non-uniformities in sonar, radar, and holographic acoustic imaging systems
US4206653A (en) 1975-10-02 1980-06-10 E M I Limited Ultrasonic apparatus
US4339952A (en) 1979-04-26 1982-07-20 Ontario Cancer Institute Cylindrical transducer ultrasonic scanner
EP0031614A1 (en) 1979-12-17 1981-07-08 North American Philips Corporation Curved array of sequenced ultrasound transducers
US4526168A (en) 1981-05-14 1985-07-02 Siemens Aktiengesellschaft Apparatus for destroying calculi in body cavities
US4586512A (en) * 1981-06-26 1986-05-06 Thomson-Csf Device for localized heating of biological tissues
US4441486A (en) * 1981-10-27 1984-04-10 Board Of Trustees Of Leland Stanford Jr. University Hyperthermia system
US4454597A (en) 1982-05-03 1984-06-12 The United States Of America As Represented By The Secretary Of The Navy Conformal array compensating beamformer
US4636964A (en) 1982-05-04 1987-01-13 Krautkramer-Branson, Inc. Method and system for generating and adjusting a predetermined quantity of mutually independent direct current voltages
US4478083A (en) 1982-06-30 1984-10-23 Siemens Aktiengesellschaft Plane reconstruction ultrasound tomography device
US4554925A (en) 1982-07-07 1985-11-26 Picker International, Ltd. Nuclear magnetic resonance imaging method
US4858597A (en) 1983-06-01 1989-08-22 Richard Wolf Gmbh Piezoelectric transducer for the destruction of concretions within an animal body
US4505156A (en) 1983-06-21 1985-03-19 Sound Products Company L.P. Method and apparatus for switching multi-element transducer arrays
US4537074A (en) 1983-09-12 1985-08-27 Technicare Corporation Annular array ultrasonic transducers
US4549533A (en) 1984-01-30 1985-10-29 University Of Illinois Apparatus and method for generating and directing ultrasound
US4662222A (en) 1984-12-21 1987-05-05 Johnson Steven A Apparatus and method for acoustic imaging using inverse scattering techniques
US4865042A (en) 1985-08-16 1989-09-12 Hitachi, Ltd. Ultrasonic irradiation system
US4889122A (en) 1985-11-29 1989-12-26 Aberdeen University Divergent ultrasound arrays
US4937767A (en) 1986-12-24 1990-06-26 Hewlett-Packard Company Method and apparatus for adjusting the intensity profile of an ultrasound beam
US4888746A (en) 1987-09-24 1989-12-19 Richard Wolf Gmbh Focussing ultrasound transducer
US5209221A (en) 1988-03-01 1993-05-11 Richard Wolf Gmbh Ultrasonic treatment of pathological tissue
US4893284A (en) 1988-05-27 1990-01-09 General Electric Company Calibration of phased array ultrasound probe
US4893624A (en) 1988-06-21 1990-01-16 Massachusetts Institute Of Technology Diffuse focus ultrasound hyperthermia system
US5211160A (en) 1988-09-14 1993-05-18 Interpore Orthopaedics, Inc. Ultrasonic orthopedic treatment head and body-mounting means therefor
WO1991000059A1 (en) 1989-07-03 1991-01-10 Institut National De La Sante Et De La Recherche Medicale Equipment for obtaining medical, pharmacological or other data by nuclear and echographic magnetic resonance
US5666954A (en) 1991-03-05 1997-09-16 Technomed Medical Systems Inserm-Institut National De La Sante Et De La Recherche Medicale Therapeutic endo-rectal probe, and apparatus constituting an application thereof for destroying cancer tissue, in particular of the prostate, and preferably in combination with an imaging endo-cavitary-probe
US5474071A (en) 1991-03-05 1995-12-12 Technomed Medical Systems Therapeutic endo-rectal probe and apparatus constituting an application thereof for destroying cancer tissue, in particular of the prostate, and preferably in combination with an imaging endo-cavitary-probe
US5435312A (en) 1991-05-31 1995-07-25 Spivey; Brett A. Acoustic imaging device
US5307816A (en) 1991-08-21 1994-05-03 Kabushiki Kaisha Toshiba Thrombus resolving treatment apparatus
US5291890A (en) 1991-08-29 1994-03-08 General Electric Company Magnetic resonance surgery using heat waves produced with focussed ultrasound
US5601526A (en) 1991-12-20 1997-02-11 Technomed Medical Systems Ultrasound therapy apparatus delivering ultrasound waves having thermal and cavitation effects
EP0558029B1 (en) 1992-02-28 2002-12-04 Kabushiki Kaisha Toshiba Apparatus for ultrasonic wave medical treatment using computed tomography
JPH05300910A (en) 1992-02-28 1993-11-16 Toshiba Corp Ultrasonic medical treatment system
JPH11313833A (en) 1992-02-28 1999-11-16 Toshiba Corp Ultrasonic therapeutic device
US5485839A (en) * 1992-02-28 1996-01-23 Kabushiki Kaisha Toshiba Method and apparatus for ultrasonic wave medical treatment using computed tomography
US5759162A (en) 1992-03-10 1998-06-02 Siemens Aktiengesellschaft Method and apparatus for ultrasound tissue therapy
US5247935A (en) 1992-03-19 1993-09-28 General Electric Company Magnetic resonance guided focussed ultrasound surgery
US5501655A (en) * 1992-03-31 1996-03-26 Massachusetts Institute Of Technology Apparatus and method for acoustic heat generation and hyperthermia
US5271400A (en) 1992-04-01 1993-12-21 General Electric Company Tracking system to monitor the position and orientation of a device using magnetic resonance detection of a sample contained within the device
US5318025A (en) 1992-04-01 1994-06-07 General Electric Company Tracking system to monitor the position and orientation of a device using multiplexed magnetic resonance detection
US5435304A (en) * 1992-04-24 1995-07-25 Siemens Aktiengesellschaft Method and apparatus for therapeutic treatment with focussed acoustic waves switchable between a locating mode and a therapy mode
DE4345308C2 (en) 1992-07-15 2001-02-01 Fukuda Denshi Kk Medical ultrasonic diagnosis system
US5275165A (en) 1992-11-06 1994-01-04 General Electric Company Magnetic resonance guided ultrasound therapy system with inclined track to move transducers in a small vertical space
US5743863A (en) 1993-01-22 1998-04-28 Technomed Medical Systems And Institut National High-intensity ultrasound therapy method and apparatus with controlled cavitation effect and reduced side lobes
US5391140A (en) 1993-01-29 1995-02-21 Siemens Aktiengesellschaft Therapy apparatus for locating and treating a zone in the body of a life form with acoustic waves
US5526815A (en) * 1993-01-29 1996-06-18 Siemens Aktiengesellschat Therapy apparatus for locating and treating a zone located in the body of a life form with acoustic waves
US5590653A (en) 1993-03-10 1997-01-07 Kabushiki Kaisha Toshiba Ultrasonic wave medical treatment apparatus suitable for use under guidance of magnetic resonance imaging
US5897495A (en) 1993-03-10 1999-04-27 Kabushiki Kaisha Toshiba Ultrasonic wave medical treatment apparatus suitable for use under guidance of magnetic resonance imaging
US5553618A (en) 1993-03-12 1996-09-10 Kabushiki Kaisha Toshiba Method and apparatus for ultrasound medical treatment
US5722411A (en) 1993-03-12 1998-03-03 Kabushiki Kaisha Toshiba Ultrasound medical treatment apparatus with reduction of noise due to treatment ultrasound irradiation at ultrasound imaging device
US5307812A (en) 1993-03-26 1994-05-03 General Electric Company Heat surgery system monitored by real-time magnetic resonance profiling
US5327884A (en) 1993-03-26 1994-07-12 General Electric Company Heat surgery system monitored by real-time magnetic resonance temperature profiling
US5323779A (en) 1993-03-26 1994-06-28 General Electric Company Heat surgery system monitored by real-time magnetic resonance temperature profiling
US6004269A (en) 1993-07-01 1999-12-21 Boston Scientific Corporation Catheters for imaging, sensing electrical potentials, and ablating tissue
US5379642A (en) 1993-07-19 1995-01-10 Diasonics Ultrasound, Inc. Method and apparatus for performing imaging
US5413550A (en) 1993-07-21 1995-05-09 Pti, Inc. Ultrasound therapy system with automatic dose control
US5368031A (en) 1993-08-29 1994-11-29 General Electric Company Magnetic resonance surgery using heat waves produced with a laser fiber
US5329930A (en) 1993-10-12 1994-07-19 General Electric Company Phased array sector scanner with multiplexed acoustic transducer elements
US5368032A (en) 1993-11-09 1994-11-29 General Electric Company Manually positioned focussed energy system guided by medical imaging
US5526814A (en) 1993-11-09 1996-06-18 General Electric Company Automatically positioned focussed energy system guided by medical imaging
US5643179A (en) 1993-12-28 1997-07-01 Kabushiki Kaisha Toshiba Method and apparatus for ultrasonic medical treatment with optimum ultrasonic irradiation control
US5665054A (en) 1994-01-27 1997-09-09 Technomed Medical Systems S.A. Control method for hyperthermia treatment apparatus using ultrasound
US5507790A (en) 1994-03-21 1996-04-16 Weiss; William V. Method of non-invasive reduction of human site-specific subcutaneous fat tissue deposits by accelerated lipolysis metabolism
US5739625A (en) 1994-05-09 1998-04-14 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Island Segmented ring transducers
US5549638A (en) 1994-05-17 1996-08-27 Burdette; Everette C. Ultrasound device for use in a thermotherapy apparatus
US5687729A (en) 1994-06-22 1997-11-18 Siemens Aktiengesellschaft Source of therapeutic acoustic waves introducible into the body of a patient
US5676673A (en) 1994-09-15 1997-10-14 Visualization Technology, Inc. Position tracking and imaging system with error detection for use in medical applications
US5694936A (en) 1994-09-17 1997-12-09 Kabushiki Kaisha Toshiba Ultrasonic apparatus for thermotherapy with variable frequency for suppressing cavitation
US5443068A (en) 1994-09-26 1995-08-22 General Electric Company Mechanical positioner for magnetic resonance guided ultrasound therapy
US5490840A (en) 1994-09-26 1996-02-13 General Electric Company Targeted thermal release of drug-polymer conjugates
US5520188A (en) 1994-11-02 1996-05-28 Focus Surgery Inc. Annular array transducer
US5662170A (en) 1994-11-22 1997-09-02 Baker Hughes Incorporated Method of drilling and completing wells
US5573497A (en) 1994-11-30 1996-11-12 Technomed Medical Systems And Institut National High-intensity ultrasound therapy method and apparatus with controlled cavitation effect and reduced side lobes
US5617371A (en) 1995-02-08 1997-04-01 Diagnostic/Retrieval Systems, Inc. Method and apparatus for accurately determing the location of signal transducers in a passive sonar or other transducer array system
US5938608A (en) 1995-03-03 1999-08-17 Siemens Aktiengesellschaft Therapy apparatus for carrying out treatment with focused ultrasound
US5984881A (en) 1995-03-31 1999-11-16 Kabushiki Kaisha Toshiba Ultrasound therapeutic apparatus using a therapeutic ultrasonic wave source and an ultrasonic probe
US6334846B1 (en) 1995-03-31 2002-01-01 Kabushiki Kaisha Toshiba Ultrasound therapeutic apparatus
US6267734B1 (en) 1995-03-31 2001-07-31 Kabushiki Kaisha Toshiba Ultrasound therapeutic apparatus
US5617857A (en) 1995-06-06 1997-04-08 Image Guided Technologies, Inc. Imaging system having interactive medical instruments and methods
US5605154A (en) 1995-06-06 1997-02-25 Duke University Two-dimensional phase correction using a deformable ultrasonic transducer array
US5582578A (en) 1995-08-01 1996-12-10 Duke University Method for the comminution of concretions
US5711300A (en) 1995-08-16 1998-01-27 General Electric Company Real time in vivo measurement of temperature changes with NMR imaging
US5590657A (en) 1995-11-06 1997-01-07 The Regents Of The University Of Michigan Phased array ultrasound system and method for cardiac ablation
US5938600A (en) 1995-12-14 1999-08-17 U.S. Philips Corporation Method and device for heating by means of ultrasound
US5762616A (en) 1996-03-15 1998-06-09 Exogen, Inc. Apparatus for ultrasonic treatment of sites corresponding to the torso
US5752515A (en) 1996-08-21 1998-05-19 Brigham & Women's Hospital Methods and apparatus for image-guided ultrasound delivery of compounds through the blood-brain barrier
US5823962A (en) * 1996-09-02 1998-10-20 Siemens Aktiengesellschaft Ultrasound transducer for diagnostic and therapeutic use
US5769790A (en) 1996-10-25 1998-06-23 General Electric Company Focused ultrasound surgery system guided by ultrasound imaging
US5810008A (en) 1996-12-03 1998-09-22 Isg Technologies Inc. Apparatus and method for visualizing ultrasonic images
US20020188229A1 (en) 1997-02-06 2002-12-12 Ryaby John P. Method and apparatus for cartilage growth stimulation
US5817036A (en) 1997-02-20 1998-10-06 General Electric Company System and method for treatment of a prostate with a phase fresnel probe
US5873845A (en) 1997-03-17 1999-02-23 General Electric Company Ultrasound transducer with focused ultrasound refraction plate
EP0875203A2 (en) 1997-04-03 1998-11-04 SonoSight, Inc. Ultrasonic array transducer for a hand held diagnostic instrument
US6322527B1 (en) 1997-04-18 2001-11-27 Exogen, Inc. Apparatus for ultrasonic bone treatment
US6263230B1 (en) 1997-05-08 2001-07-17 Lucent Medical Systems, Inc. System and method to determine the location and orientation of an indwelling medical device
CN1257414A (en) 1997-05-23 2000-06-21 外科器械股份有限公司 MRI-guided therapeutic unit and method
US6374132B1 (en) 1997-05-23 2002-04-16 Transurgical, Inc. MRI-guided therapeutic unit and methods
US6128522A (en) 1997-05-23 2000-10-03 Transurgical, Inc. MRI-guided therapeutic unit and methods
WO1998052465A1 (en) 1997-05-23 1998-11-26 Transurgical, Inc. Mri-guided therapeutic unit and methods
US6023636A (en) 1997-06-25 2000-02-08 Siemens Aktiengesellschaft Magnetic resonance apparatus and method for determining the location of a positionable object in a subject
US20030060820A1 (en) 1997-07-08 2003-03-27 Maguire Mark A. Tissue ablation device assembly and method for electrically isolating a pulmonary vein ostium from an atrial wall
US6193659B1 (en) 1997-07-15 2001-02-27 Acuson Corporation Medical ultrasonic diagnostic imaging method and apparatus
US6128958A (en) 1997-09-11 2000-10-10 The Regents Of The University Of Michigan Phased array system architecture
US6113558A (en) 1997-09-29 2000-09-05 Angiosonics Inc. Pulsed mode lysis method
US6071239A (en) 1997-10-27 2000-06-06 Cribbs; Robert W. Method and apparatus for lipolytic therapy using ultrasound energy
US6113559A (en) 1997-12-29 2000-09-05 Klopotek; Peter J. Method and apparatus for therapeutic treatment of skin with ultrasound
US6397094B1 (en) 1998-01-09 2002-05-28 Koninklijke Philips Electronics N.V. MR method utilizing microcoils situated in the examination zone
US5947900A (en) 1998-04-13 1999-09-07 General Electric Company Dynamic scan plane tracking using MR position monitoring
JP2002505596A5 (en) 1998-05-22 2005-12-08
US6042556A (en) 1998-09-04 2000-03-28 University Of Washington Method for determining phase advancement of transducer elements in high intensity focused ultrasound
US20060052701A1 (en) 1998-09-18 2006-03-09 University Of Washington Treatment of unwanted tissue by the selective destruction of vasculature providing nutrients to the tissue
US6425867B1 (en) 1998-09-18 2002-07-30 University Of Washington Noise-free real time ultrasonic imaging of a treatment site undergoing high intensity focused ultrasound therapy
EP1132054A1 (en) 1998-10-26 2001-09-12 Hitachi, Ltd. Ultrasonic medical treating device
US6511428B1 (en) 1998-10-26 2003-01-28 Hitachi, Ltd. Ultrasonic medical treating device
US7155271B2 (en) 1998-11-04 2006-12-26 Johns Hopkins University School Of Medicine System and method for magnetic-resonance-guided electrophysiologic and ablation procedures
US6246896B1 (en) 1998-11-24 2001-06-12 General Electric Company MRI guided ablation system
WO2000031614A1 (en) 1998-11-25 2000-06-02 Flashpoint Technology, Inc. Digital image capture devices and methods and systems associated therewith
US6289233B1 (en) 1998-11-25 2001-09-11 General Electric Company High speed tracking of interventional devices using an MRI system
US6424597B1 (en) 1998-11-27 2002-07-23 Commissariat A L'energie Atomique Multielements ultrasonic contact transducer
US6309355B1 (en) 1998-12-22 2001-10-30 The Regents Of The University Of Michigan Method and assembly for performing ultrasound surgery using cavitation
US6413216B1 (en) 1998-12-22 2002-07-02 The Regents Of The University Of Michigan Method and assembly for performing ultrasound surgery using cavitation
US6428532B1 (en) 1998-12-30 2002-08-06 The General Hospital Corporation Selective tissue targeting by difference frequency of two wavelengths
US6461314B1 (en) 1999-02-02 2002-10-08 Transurgical, Inc. Intrabody hifu applicator
US20030004439A1 (en) 1999-02-02 2003-01-02 Transurgical, Inc. Intrabody HIFU applicator
US6652461B1 (en) 1999-04-15 2003-11-25 F.R.A.Y Project Ltd. Ultrasound device for three-dimensional imaging of internal structure of a body part
US6676601B1 (en) 1999-05-26 2004-01-13 Technomed Medical Systems, S.A. Apparatus and method for location and treatment using ultrasound
US7001379B2 (en) 1999-06-25 2006-02-21 Boston Scientific Scimed, Inc. Method and system for heating solid tissue
US20040147919A1 (en) 1999-06-25 2004-07-29 Scimed Life Systems, Inc. Method and system for heating solid tissue
US6317619B1 (en) 1999-07-29 2001-11-13 U.S. Philips Corporation Apparatus, methods, and devices for magnetic resonance imaging controlled by the position of a moveable RF coil
US6242915B1 (en) 1999-08-27 2001-06-05 General Electric Company Field-frequency lock system for magnetic resonance system
US6566878B1 (en) 1999-09-09 2003-05-20 Hitachi Medical Corporation Magnetic resonance imaging device and method therefor
US6599256B1 (en) 1999-09-10 2003-07-29 Transurgical, Inc. Occlusion of tubular anatomical structures by energy application
US20050240126A1 (en) 1999-09-17 2005-10-27 University Of Washington Ultrasound guided high intensity focused ultrasound treatment of nerves
US7510536B2 (en) 1999-09-17 2009-03-31 University Of Washington Ultrasound guided high intensity focused ultrasound treatment of nerves
US6626855B1 (en) 1999-11-26 2003-09-30 Therus Corpoation Controlled high efficiency lesion formation using high intensity ultrasound
US6618608B1 (en) 1999-11-30 2003-09-09 Txsonics, Ltd. Thermal imaging of fat and muscle using a simultaneous phase and magnitude double echo sequence
WO2001043640A3 (en) 1999-12-15 2001-12-13 Koninkl Philips Electronics Nv Diagnostic imaging system with ultrasound probe
US20010031922A1 (en) 1999-12-23 2001-10-18 Therus Corporation Ultrasound transducers for imaging and therapy
US20050096542A1 (en) 1999-12-23 2005-05-05 Lee Weng Ultrasound transducers for imaging and therapy
US6719694B2 (en) 1999-12-23 2004-04-13 Therus Corporation Ultrasound transducers for imaging and therapy
US20060229594A1 (en) 2000-01-19 2006-10-12 Medtronic, Inc. Method for guiding a medical device
WO2001058337A2 (en) 2000-02-09 2001-08-16 Spencer Technologies, Inc. Method and apparatus combining diagnostic ultrasound with therapeutic ultrasound to enhance thrombolysis
WO2001066189A1 (en) 2000-03-09 2001-09-13 Transurgical, Inc. Hifu application with feedback control using bubble detection
FR2806611A1 (en) 2000-03-22 2001-09-28 Hossein Kafai Medical ultrasonic imaging device for examination of jaw region uses ultrasonic probes arranged on either side of face
US6554826B1 (en) 2000-04-21 2003-04-29 Txsonics-Ltd Electro-dynamic phased array lens for controlling acoustic wave propagation
WO2001080709A2 (en) 2000-04-21 2001-11-01 Txsonics Ltd. Systems and methods for creating longer necrosed volumes using a phased array focused ultrasound system
US6543272B1 (en) 2000-04-21 2003-04-08 Insightec-Txsonics Ltd. Systems and methods for testing and calibrating a focused ultrasound transducer array
US6419648B1 (en) 2000-04-21 2002-07-16 Insightec-Txsonics Ltd. Systems and methods for reducing secondary hot spots in a phased array focused ultrasound system
US6613004B1 (en) 2000-04-21 2003-09-02 Insightec-Txsonics, Ltd. Systems and methods for creating longer necrosed volumes using a phased array focused ultrasound system
US6392330B1 (en) 2000-06-05 2002-05-21 Pegasus Technologies Ltd. Cylindrical ultrasound receivers and transceivers formed from piezoelectric film
US20020035779A1 (en) 2000-06-09 2002-03-28 Robert Krieg Method for three-dimensionally correcting distortions and magnetic resonance apparatus for implementing the method
US6761691B2 (en) 2000-07-21 2004-07-13 Fuji Photo Film Co., Ltd. Image forming method used in ultrasonic diagnosis, ultrasonic diagnostic apparatus, signal processing apparatus, and recording medium for recording signal processing program
US6506171B1 (en) 2000-07-27 2003-01-14 Insightec-Txsonics, Ltd System and methods for controlling distribution of acoustic energy around a focal point using a focused ultrasound system
US6733450B1 (en) 2000-07-27 2004-05-11 Texas Systems, Board Of Regents Therapeutic methods and apparatus for use of sonication to enhance perfusion of tissue
US6582381B1 (en) 2000-07-31 2003-06-24 Txsonics Ltd. Mechanical positioner for MRI guided ultrasound therapy system
US6612988B2 (en) 2000-08-29 2003-09-02 Brigham And Women's Hospital, Inc. Ultrasound therapy
US6679855B2 (en) 2000-11-07 2004-01-20 Gerald Horn Method and apparatus for the correction of presbyopia using high intensity focused ultrasound
US6613005B1 (en) 2000-11-28 2003-09-02 Insightec-Txsonics, Ltd. Systems and methods for steering a focused ultrasound array
US6618620B1 (en) 2000-11-28 2003-09-09 Txsonics Ltd. Apparatus for controlling thermal dosing in an thermal treatment system
US6666833B1 (en) 2000-11-28 2003-12-23 Insightec-Txsonics Ltd Systems and methods for focussing an acoustic energy beam transmitted through non-uniform tissue medium
US6506154B1 (en) 2000-11-28 2003-01-14 Insightec-Txsonics, Ltd. Systems and methods for controlling a phased array focused ultrasound system
US6475150B2 (en) 2000-12-01 2002-11-05 The Regents Of The University Of California System and method for ultrasonic tomography
US6770031B2 (en) 2000-12-15 2004-08-03 Brigham And Women's Hospital, Inc. Ultrasound therapy
WO2002058791A1 (en) 2000-12-15 2002-08-01 The Brigham And Women's Hospital, Inc. Method and system for calculating phase and amplitude corrections in ultrasound therapy
US6626854B2 (en) 2000-12-27 2003-09-30 Insightec - Txsonics Ltd. Systems and methods for ultrasound assisted lipolysis
US20020082589A1 (en) 2000-12-27 2002-06-27 Insightec - Image Guided Treatement Ltd. Systems and methods for ultrasound assisted lipolysis
US6645162B2 (en) 2000-12-27 2003-11-11 Insightec - Txsonics Ltd. Systems and methods for ultrasound assisted lipolysis
DE10102317A1 (en) 2001-01-19 2002-08-14 Hmt Ag Method and device for applying pressure waves to the body of a living being
US20040068186A1 (en) 2001-01-22 2004-04-08 Kazunari Ishida Ultrasonic therapeutic probe and ultrasonic device
US7094205B2 (en) 2001-04-06 2006-08-22 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California High-resolution 3D ultrasonic transmission imaging
US6478739B1 (en) 2001-05-11 2002-11-12 The Procter & Gamble Company Ultrasonic breast examination system
US6559644B2 (en) 2001-05-30 2003-05-06 Insightec - Txsonics Ltd. MRI-based temperature mapping with error compensation
US6735461B2 (en) 2001-06-19 2004-05-11 Insightec-Txsonics Ltd Focused ultrasound system with MRI synchronization
WO2003013654A1 (en) 2001-08-09 2003-02-20 Exogen, Inc. Method and means for controlling acoustic modes in tissue healing applications
US6788619B2 (en) 2001-09-07 2004-09-07 Shell Oil Company Concentrating seismic energy in a selected target point in an underground formation
US7264597B2 (en) 2001-10-04 2007-09-04 Institut National De La Sante Et De Lacrecherchedmedicale Device and method for producing high-pressure ultrasonic pulses
US6961606B2 (en) 2001-10-19 2005-11-01 Koninklijke Philips Electronics N.V. Multimodality medical imaging system and method with separable detector devices
US7175596B2 (en) 2001-10-29 2007-02-13 Insightec-Txsonics Ltd System and method for sensing and locating disturbances in an energy path of a focused ultrasound system
US6770039B2 (en) 2001-11-09 2004-08-03 Duke University Method to reduce tissue injury in shock wave lithotripsy
US6790180B2 (en) 2001-12-03 2004-09-14 Insightec-Txsonics Ltd. Apparatus, systems, and methods for measuring power output of an ultrasound transducer
US6522142B1 (en) 2001-12-14 2003-02-18 Insightec-Txsonics Ltd. MRI-guided temperature mapping of tissue undergoing thermal treatment
WO2003070105A1 (en) 2002-02-20 2003-08-28 Liposonix, Inc. Ultrasonic treatment and imaging of adipose tissue
US6824516B2 (en) 2002-03-11 2004-11-30 Medsci Technologies, Inc. System for examining, mapping, diagnosing, and treating diseases of the prostate
US7128711B2 (en) 2002-03-25 2006-10-31 Insightec, Ltd. Positioning systems and methods for guided ultrasound therapy systems
US20030187371A1 (en) 2002-03-27 2003-10-02 Insightec-Txsonics Ltd. Systems and methods for enhanced focused ultrasound ablation using microbubbles
WO2003097162A2 (en) 2002-03-27 2003-11-27 Insightec-Txsonics Ltd Enhanced focused ultrasound ablation using microbubbles
US6951540B2 (en) 2002-05-10 2005-10-04 Regents Of The University Of Minnesota Ultrasound imaging system and method using non-linear post-beamforming filter
US20040030251A1 (en) 2002-05-10 2004-02-12 Ebbini Emad S. Ultrasound imaging system and method using non-linear post-beamforming filter
WO2003098232A2 (en) 2002-05-17 2003-11-27 Case Western Reserve University Chemical shift markers for improved wireless fiducial marker tracking
US7264592B2 (en) 2002-06-28 2007-09-04 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Scanning devices for three-dimensional ultrasound mammography
US6705994B2 (en) 2002-07-08 2004-03-16 Insightec - Image Guided Treatment Ltd Tissue inhomogeneity correction in ultrasound imaging
US7077820B1 (en) 2002-10-21 2006-07-18 Advanced Medical Optics, Inc. Enhanced microburst ultrasonic power delivery system and method
US20050203444A1 (en) 2002-10-25 2005-09-15 Compex Medical S.A. Ultrasound therapeutic device
US6629929B1 (en) 2002-11-08 2003-10-07 Koninklijke Philips Electronics N.V. Method and apparatus for automatically setting the transmit aperture and apodization of an ultrasound transducer array
US7267650B2 (en) 2002-12-16 2007-09-11 Cardiac Pacemakers, Inc. Ultrasound directed guiding catheter system and method
US20040122323A1 (en) 2002-12-23 2004-06-24 Insightec-Txsonics Ltd Tissue aberration corrections in ultrasound therapy
US20060052661A1 (en) 2003-01-23 2006-03-09 Ramot At Tel Aviv University Ltd. Minimally invasive control surgical system with feedback
EP1591073A4 (en) 2003-01-31 2010-11-17 Hitachi Medical Corp Ultrasonic probe and ultrasonic device
US7344509B2 (en) 2003-04-17 2008-03-18 Kullervo Hynynen Shear mode therapeutic ultrasound
WO2004093686A1 (en) 2003-04-17 2004-11-04 The Brigham & Women's Hospital, Inc. Shear mode diagnostic ultrasound
US7175599B2 (en) 2003-04-17 2007-02-13 Brigham And Women's Hospital, Inc. Shear mode diagnostic ultrasound
US20040210134A1 (en) 2003-04-17 2004-10-21 Kullervo Hynynen Shear mode therapeutic ultrasound
US20060106300A1 (en) 2003-04-24 2006-05-18 Universiteit Utrecht Holding B.V. Selective MR imaging of magnetic susceptibility deviations
US20040236253A1 (en) 2003-05-22 2004-11-25 Insightec-Image Guided Treatment Ltd. Acoustic beam forming in phased arrays including large numbers of transducer elements
US20100056962A1 (en) 2003-05-22 2010-03-04 Kobi Vortman Acoustic Beam Forming in Phased Arrays Including Large Numbers of Transducer Elements
US7611462B2 (en) 2003-05-22 2009-11-03 Insightec-Image Guided Treatment Ltd. Acoustic beam forming in phased arrays including large numbers of transducer elements
US7377900B2 (en) 2003-06-02 2008-05-27 Insightec - Image Guided Treatment Ltd. Endo-cavity focused ultrasound transducer
US20070197918A1 (en) 2003-06-02 2007-08-23 Insightec - Image Guided Treatment Ltd. Endo-cavity focused ultrasound transducer
US20060173385A1 (en) 2003-06-04 2006-08-03 Lars Lidgren Ultrasound probe having a central opening
US20040267126A1 (en) 2003-06-25 2004-12-30 Aloka Co., Ltd. Ultrasound diagnosis apparatus
US7505805B2 (en) 2003-07-11 2009-03-17 Foundation For Biomedical Research And Innovation Self-referencing/body motion tracking non-invasive internal temperature distribution measurement method and apparatus using magnetic resonance tomographic imaging technique
US20070055140A1 (en) 2003-07-11 2007-03-08 Kagayaki Kuroda Self-referencing/body motion tracking non-invasive internal temperature distribution measurement method and apparatus using magnetic resonance tomographic imaging technique
US20050033201A1 (en) 2003-08-07 2005-02-10 Olympus Corporation Ultrasonic surgical system
US20050131301A1 (en) 2003-12-12 2005-06-16 Michael Peszynski Ultrasound probe receptacle
WO2005058029A3 (en) 2003-12-17 2005-12-22 Mentor Graphics Corp Mask creation with hierarchy management using cover cells
US7603162B2 (en) 2004-01-28 2009-10-13 Siemens Aktiengesellschaft Imaging tomography apparatus with fluid-containing chambers forming out-of-balance compensating weights for a rotating part
US20050251046A1 (en) 2004-03-29 2005-11-10 Yuko Yamamoto Probe array producing method
EP1582886B1 (en) 2004-04-02 2012-08-15 Universität Zürich Magnetic resonance apparatus with magnetic field detectors
US20080228081A1 (en) 2004-04-02 2008-09-18 Koninklijke Philips Electronics, N.V. Ultrasonic Intracavity Probe For 3D Imaging
US7505808B2 (en) 2004-04-28 2009-03-17 Sunnybrook Health Sciences Centre Catheter tracking with phase information
EP1774920A1 (en) 2004-06-21 2007-04-18 Hiroshi Furuhata Ultrasonic brain infarction treating device
US7699780B2 (en) 2004-08-11 2010-04-20 Insightec—Image-Guided Treatment Ltd. Focused ultrasound system with adaptive anatomical aperture shaping
WO2006018837A3 (en) 2004-08-17 2007-05-18 Technion Res & Dev Foundation Ultrasonic image-guided tissue-damaging procedure
US20060052706A1 (en) 2004-08-20 2006-03-09 Kullervo Hynynen Phased array ultrasound for cardiac ablation
US20060058678A1 (en) 2004-08-26 2006-03-16 Insightec - Image Guided Treatment Ltd. Focused ultrasound system for surrounding a body tissue mass
WO2006025001A1 (en) 2004-09-01 2006-03-09 Koninklijke Philips Electronics, N.V. Magnetic resonance marker based position and orientation probe
US7452357B2 (en) 2004-10-22 2008-11-18 Ethicon Endo-Surgery, Inc. System and method for planning treatment of tissue
US20060184069A1 (en) 2005-02-02 2006-08-17 Vaitekunas Jeffrey J Focused ultrasound for pain reduction
US7553284B2 (en) 2005-02-02 2009-06-30 Vaitekunas Jeffrey J Focused ultrasound for pain reduction
WO2006087649A1 (en) 2005-02-17 2006-08-24 Koninklijke Philips Electronics, N.V. Method and apparatus for the visualization of the focus generated using focused ultrasound
US20060206105A1 (en) 2005-03-09 2006-09-14 Rajiv Chopra Treatment of diseased tissue using controlled ultrasonic heating
WO2006119572A1 (en) 2005-05-12 2006-11-16 Compumedics Medical Innovation Pty Ltd Ultrasound diagnosis and treatment apparatus
US20070016039A1 (en) 2005-06-21 2007-01-18 Insightec-Image Guided Treatment Ltd. Controlled, non-linear focused ultrasound treatment
US20070066897A1 (en) 2005-07-13 2007-03-22 Sekins K M Systems and methods for performing acoustic hemostasis of deep bleeding trauma in limbs
US20070073135A1 (en) 2005-09-13 2007-03-29 Warren Lee Integrated ultrasound imaging and ablation probe
US20070098232A1 (en) 2005-09-14 2007-05-03 University Of Washington Using optical scattering to measure properties of ultrasound contrast agent shells
US20070167781A1 (en) 2005-11-23 2007-07-19 Insightec Ltd. Hierarchical Switching in Ultra-High Density Ultrasound Array
EP1790384A1 (en) 2005-11-23 2007-05-30 Siemens Medical Solutions USA, Inc. Contrast agent augmented ultrasound therapy system with ultrasound imaging guidance for thrombus treatment
US20080312562A1 (en) 2005-12-14 2008-12-18 Koninklijke Philips Electronics, N.V. Method and Apparatus for Guidance and Application of High Intensity Focused Ultrasound for Control of Bleeding Due to Severed Limbs
WO2007073551A1 (en) 2005-12-22 2007-06-28 Boston Scientific Scimed, Inc. Device and method for determining the location of a vascular opening prior to application of hifu energy to seal the opening
WO2007093998A1 (en) 2006-02-16 2007-08-23 Syneron Medical Ltd. Method and apparatus for treatment of adipose tissue
US20070219470A1 (en) 2006-03-08 2007-09-20 Talish Roger J System and method for providing therapeutic treatment using a combination of ultrasound, electro-stimulation and vibrational stimulation
US20080082026A1 (en) 2006-04-26 2008-04-03 Rita Schmidt Focused ultrasound system with far field tail suppression
WO2008075203A2 (en) 2006-06-21 2008-06-26 Martinswerk Gmbh Process for the production of aluminum hydroxide
US20080027342A1 (en) 2006-07-28 2008-01-31 Mattias Rouw Prioritized Multicomplexor Sensing Circuit
US20080031090A1 (en) 2006-08-01 2008-02-07 Insightec, Ltd Transducer surface mapping
US7652410B2 (en) 2006-08-01 2010-01-26 Insightec Ltd Ultrasound transducer with non-uniform elements
US7535794B2 (en) 2006-08-01 2009-05-19 Insightec, Ltd. Transducer surface mapping
US20080033278A1 (en) 2006-08-01 2008-02-07 Insightec Ltd. System and method for tracking medical device using magnetic resonance detection
WO2008039449A1 (en) 2006-09-27 2008-04-03 Siemens Medical Solutions Usa, Inc. Automated contrast agent augmented ultrasound therapy for thrombus treatment
US20080108900A1 (en) 2006-09-29 2008-05-08 Chih-Kung Lee Ultrasound transducer apparatus
US20080183077A1 (en) 2006-10-19 2008-07-31 Siemens Corporate Research, Inc. High intensity focused ultrasound path determination
WO2008050278A1 (en) 2006-10-23 2008-05-02 Koninklijke Philips Electronics, N.V. Symmetric and preferentially steered random arrays for ultrasound therapy
WO2008119054A1 (en) 2007-03-27 2008-10-02 Abqmr, Inc. System and method for detecting labeled entities using microcoil magnetic mri
US7511501B2 (en) 2007-05-11 2009-03-31 General Electric Company Systems and apparatus for monitoring internal temperature of a gradient coil
US20090088623A1 (en) 2007-10-01 2009-04-02 Insightec, Ltd. Motion compensated image-guided focused ultrasound therapy system
US20090096450A1 (en) 2007-10-12 2009-04-16 Joerg Roland Bo field drift correction in a temperature map generated by magnetic resonance tomography
WO2009055587A1 (en) 2007-10-23 2009-04-30 Abqmr, Inc. Microcoil magnetic resonance detectors
WO2009094554A2 (en) 2008-01-25 2009-07-30 The Regents Of The University Of Michigan Histotripsy for thrombolysis

Non-Patent Citations (67)

* Cited by examiner, † Cited by third party
Title
"Abstract" Focus Surgery, http://www.focus-surgery.com/Sanghvi.htm, accessed Jan. 3, 2003.
"How does HIFU create a lesion?" http://www.edap-hifu.com/eng/physicians/hifu/2d-hifu-lesion.htm, accessed Jan. 3, 2003.
"How is Ablatherm treatment performed?" http://www.edap-hifu.com/eng/physicians/hifu/3c-treatment-treat-description.htm, accessed Jan. 3, 2003.
"Prostate Cancer Phase I Clinical Trials Using High Intensity Focused Ultrasound (HIFU)," Focus Surgery, http://www.focus-surgery.com/PCT%20Treatment%20with%20HIFU.htm, accessed Jan. 3, 2003.
"What are the physical principles?" http://www.edap-hifu.com/eng/physicians/hifu/2c-hifu-physical.htm, accessed Jan. 3, 2003.
"What is HIFU? HIFU: High Intensity Focused Ultrasound," http://www.edap-hifu.com/eng/physicians/hifu2a-hifu-overview.htm, accessed Jan. 3, 2003.
Botros et al., "A hybrid computational model for ultrasound phased-array heating in presence of strongly scattering obstacles," IEEE Trans. On Biomed. Eng., vol. 44, No. 11, pp. 1039-1050 (Nov. 1997).
Charles A. Cain, et al., "Concentric-Ring and Sector-Vortex Phased-Array Applicators for Ultrasound Hyperthermia", IEEE Transactions on Microwave Theory and Techniques, MTT-34, pp. 542-551, 1986.
Chen et al., "MR Acoustic Radiation Force Imaging: Comparison of Encoding Gradients."
Cline et al., "MR Temperature mapping of focused ultrasound surgery," Magnetic Resonance in Medicine, vol. 32, No. 6, pp. 628-636 (1994).
Cline et al., "Simultaneous magnetic resonance phase and magnitude temperature maps in muscle," Magnetic Resonance in Medicine, vol. 35, No. 3, pp. 309-315 (Mar. 1996).
CN Notice of Allowance and Issuance with English translation, dated Jan. 30, 2007 for related CN application serial No. 01819665.9, Applicant Insightec-TxSonics, Ltd (4 pages).
CN Office Action with English translation, dated Mar. 24, 2006 for related CN application serial No. 01819665.9, Applicant Insightec-TxSonics, Ltd (10 pages).
CN Response to Office Action with English translation, dated Aug. 8, 2006 for related CN application serial No. 01819665.9, Applicant Insightec-TxSonics, Ltd (12 pages).
Daum et al., "Design and evaluation of a feedback based phased array system for ultrasound surgery," IEEE Trans. Ultrason. Ferroelec. Freq. Control, vol. 45, No. 2, pp. 431-434 (1998).
de Senneville et al., "Real-time adaptive methods for treatment of mobile organs by MRI-controlled high-intensity focussed Ultrasound," Magnetic Resonance in Medicine 57:319-330 (2007).
Decision from oral proceedings of Feb. 20, 2008 for European Application No. 01 998 377.4.
EP Amendment and Response to Office Action, dated Aug. 21, 2007 for related EP application serial No. 01998377.4, Applicant Insightec-TxSonics, Ltd (5 pages).
EP Amendment and Response to Office Action, dated Jan. 8, 2007 for related EP application serial No. 01998377.4, Applicant Insightec-TxSonics, Ltd (8 pages).
EP Amendment and Response to Office Action, dated Mar. 27, 2007 for related EP application serial No. 01998377.4, Applicant Insightec-TxSonics, Ltd (10 pages).
EP Amendment and Response to Office Action, dated May 19, 2006 for related EP application serial No. 01998377.4, Applicant Insightec-TxSonics, Ltd (12 pages).
EP Office Action, dated Apr. 19, 2007 for related EP application serial No. 01998377.4, Applicant Insightec-TxSonics, Ltd (4 pages).
EP Office Action, dated Jan. 23, 2007 for related EP application serial No. 01998377.4, Applicant Insightec-TxSonics, Ltd (3 pages).
EP Office Action, dated Jun. 29, 2006 for related EP application serial No. 01998377.4, Applicant Insightec-TxSonics, Ltd (3 pages).
EP Office Action, dated Nov. 21, 2005 for related EP application serial No. 01998377.4, Applicant Insightec-TxSonics, Ltd (2 pages).
EP Supplemental Amendment and Response to Office Action, dated May 22, 2006 for related EP application serial No. 01998377.4, Applicant Insightec-TxSonics, Ltd (2 pages).
Exablate 2000 Specification, InSightec, Ltd. (2 pages).
FDA Approves Exablate 2000 as Non-invasive surgery for Fibroids, Oct. 22, 2004.
Frederic C. Vimeux MS. et al., "Real-Time Control of Focused Ultrasound Heating Based on Rapid MR Thermometry", Investigative Radiology, vol. 34, No. 3, 190-193, (c) Lippincott Williams and Wilkins, Inc.
Harvey E. Cline, Ph.D., et al., "Focused US System for MR Imaging-Guide Tumor Ablation", Radiology vol. 194, No. 3, pp. 731-738, Mar. 1995.
Herbert et al., "Energy-based adaptive focusing of waves: application to ultrasonic transcranial therapy," 8th Intl. Symp. On Therapeutic Ultrasound.
Huber et al., "A New Noninvasive Approach in Breast Cancer Therapy Using Magnetic Resonance Imaging-Guided Focussed Ultrasound Surgery," Cancer Research 61, 8441-8447 (Dec. 2001).
International Preliminary Report on Patentability in International Patent Application No. PCT/IB2004/001512, mailed Dec. 8, 2005.
International Search Report and Written Opinion in International Patent Application No. PCT/IB2004/001498, dated Aug. 31, 2004.
International Search Report and Written Opinion in International Patent Application No. PCT/IB2005/002273, mailed Dec. 20, 2005.
International Search Report and Written Opinion in International Patent Application No. PCT/IB2005/002413, mailed Nov. 22, 2005.
International Search Report and Written Opinion in International Patent Application No. PCT/IB2006/001641, mailed Sep. 25, 2006.
International Search Report and Written Opinion in International Patent Application No. PCT/IB2006/003300, mailed Feb. 14, 2008.
International Search Report and Written Opinion in International Patent Application No. PCT/IB2007/001079, mailed Dec. 10, 2007.
International Search Report and Written Opinion in International Patent Application No. PCT/IB2007/002134, mailed Dec. 13, 2007.
International Search Report and Written Opinion in International Patent Application No. PCT/IB2007/002140, mailed Dec. 29, 2008.
International Search Report and Written Opinion in International Patent Application No. PCT/IB2008/003069, mailed Apr. 27, 2009.
Jolesz et al., "Integration of interventional MRI with computer-assisted surgery," J. Magnetic Resonance Imaging. 12:69-77 (2001).
JP Office Action with English translation, dated Apr. 17, 2007 for related JP application serial No. 2002-545773, Applicant Insightec-TxSonics, Ltd (5 pages).
Kohler et al., "Volumetric HIFU Ablation guided by multiplane MRI thermometry," 8th Intl. Symp. On Therapeutic Ultrasound, edited by E.S. Ebbini, U. of Minn. (Sep. 2009).
Kowalski et al., "Optimization of electromagnetic phased-arrays for hyperthermia via magnetic resonance temperature estimation," IEEE Trans. On Biomed. Eng., vol. 49, No. 11, pp. 1229-1241 (Nov. 2002).
Kullervo Hynyen et al., "Principles of MR-Guided Focused Ultrasound", Chapter 25, pp. 237-243.
Kullervo Hynynen et al., "Principles of MR-Guided Focused Ultrasound", Chapter 25, pp. 237-243.
Maxwell et al., "Noninvasive thrombolysis using pulsed ultrasound cavitation therapy-Histotripsy," Abstract, U.S. Natl. Lib. Of Med., NIH, Ultrasound Med. Biol. (Oct. 23, 2009).
McDannold et al., "Magnetic resonance acoustic radiation force imaging," Med. Phys. vol. 35, No. 8, pp. 3748-3758 (Aug. 2008).
McDannold, et al., "Quality Assurance and System Stability of a Clinical MRI-guided focused ultrasound system: Four-year experience," Medical Physics, vol. 33, No. 11, pp. 4307-4313 (Oct. 2006).
McGough, et al., "Direct Computation of Ultrasound Phased-Array Driving Signals from a Specified Temperature Distribution for Hyperthermia," IEEE Trans. On Biomedical Engineering, vol. 39, No. 8, pp. 825-835 (Aug. 1992).
Medel et al., "Sonothrombolysis: An emerging modality for the management of stroke," Neurosurgery, vol. 65, No. 5, pp. 979-993.
Minutes of oral proceedings before the Examining Division on Feb. 20, 2008 for European Application No. 01 998 377.4.
Mougenot et al., "MR monitoring of the near-field HIFU heating," 8th Intl. Symp. On Therapeutic Ultrasound, edited by E.S. Ebbini, U. of Minn. (Sep. 2009).
Nathan McDannold, et al., "MRI Evaluation of Thermal Ablation of Tumors and Focused Ultrasound", JMRI vol. 8, No. 1, pp. 91-100, Jan./Feb. 1998.
Partial International Search Report and Written Opinion in International Patent Application No. PCT/IB2007/001079, dated Sep. 25, 2007.
PCT International Preliminary Examination Report (IPER), form PCT/IPEA/416, dated Mar. 2003, for related International Application No. PCT/IL01/01084, Applicant Insightec-TxSonics, Ltd (5 pages).
PCT International Search Report (ISR), form PCT/ISA/210 & 220, dated Mar. 26, 2002, for related International Application No. PCT/IL01/01084, Applicant Insightec-TxSonics, Ltd (7 pages).
PCT Reply to Written Opinion, dated Nov. 28, 2002, for related International Application No. PCT/IL01/01084, Applicant Insightec-TxSonics, Ltd (7 pages).
PCT Written Opinion, form PCT/IPEA/408, dated Aug. 28, 2002, for related International Application No. PCT/IL01/01084, Applicant Insightec-TxSonics, Ltd (4 pages).
Todd Fjield, et al., "The Combined Concentric-Ring and Sector-Vortex Phased Array for MRI Guided Ultrasound Surgery", IEEE Transactions on Ultrasonics, Ferroelectriccs and Frequency Control, vol. 44, No. 5, pp. 1157-1167, Sep. 1997.
Todd Fjield, et al., "The Combined Concentric-Ring and Sector-Vortex Phased Array for MRI Guided Ultrasound Surgery", IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control, vol. 44, No. 5, pp. 1157-1167, Sep. 1997.
Vykhodtseva et al., "MRI detection of the thermal effects of focused ultrasound on the brain," Ultrasound in Med. & Biol., vol. 26, No. 5, pp. 871-880 (2000).
Written Opinion in International Patent Application No. PCT/IB03/05551, mailed Sep. 10, 2004.
Written Opinion in International Patent Application No. PCT/IL01/00340, mailed Feb. 24, 2003.
Written Opinion in International Patent Application No. PCT/IL02/00477, mailed Feb. 25, 2003.

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9333038B2 (en) 2000-06-15 2016-05-10 Monteris Medical Corporation Hyperthermia treatment and probe therefore
US9387042B2 (en) 2000-06-15 2016-07-12 Monteris Medical Corporation Hyperthermia treatment and probe therefor
US20100280356A1 (en) * 2008-01-14 2010-11-04 Koninklijke Philips Electronics N.V. Therapy system with temperature control
US9687681B2 (en) * 2008-01-14 2017-06-27 Koninklijke Philips N.V. Therapy system with temperature control
US20120070058A1 (en) * 2009-06-02 2012-03-22 Koninklijke Philips Electronics N.V. Mr imaging guided therapy
US8867811B2 (en) * 2009-06-02 2014-10-21 Koninklijke Philips N.V. MR imaging guided therapy
US10188462B2 (en) 2009-08-13 2019-01-29 Monteris Medical Corporation Image-guided therapy of a tissue
US9211157B2 (en) 2009-08-13 2015-12-15 Monteris Medical Corporation Probe driver
US10610317B2 (en) 2009-08-13 2020-04-07 Monteris Medical Corporation Image-guided therapy of a tissue
US8979871B2 (en) 2009-08-13 2015-03-17 Monteris Medical Corporation Image-guided therapy of a tissue
US9510909B2 (en) 2009-08-13 2016-12-06 Monteris Medical Corporation Image-guide therapy of a tissue
US9271794B2 (en) 2009-08-13 2016-03-01 Monteris Medical Corporation Monitoring and noise masking of thermal therapy
US9981148B2 (en) 2010-10-22 2018-05-29 Insightec, Ltd. Adaptive active cooling during focused ultrasound treatment
US10548678B2 (en) 2012-06-27 2020-02-04 Monteris Medical Corporation Method and device for effecting thermal therapy of a tissue
US10835215B2 (en) 2012-09-12 2020-11-17 Convergent Life Sciences, Inc. Method and apparatus for laser ablation under ultrasound guidance
US20150141874A1 (en) * 2013-11-18 2015-05-21 Kitchener Clark Wilson Multi-beam Ultrasound Device
US9700342B2 (en) 2014-03-18 2017-07-11 Monteris Medical Corporation Image-guided therapy of a tissue
US10092367B2 (en) 2014-03-18 2018-10-09 Monteris Medical Corporation Image-guided therapy of a tissue
US9504484B2 (en) 2014-03-18 2016-11-29 Monteris Medical Corporation Image-guided therapy of a tissue
US10342632B2 (en) 2014-03-18 2019-07-09 Monteris Medical Corporation Image-guided therapy of a tissue
US9492121B2 (en) 2014-03-18 2016-11-15 Monteris Medical Corporation Image-guided therapy of a tissue
US9486170B2 (en) 2014-03-18 2016-11-08 Monteris Medical Corporation Image-guided therapy of a tissue
US10675113B2 (en) 2014-03-18 2020-06-09 Monteris Medical Corporation Automated therapy of a three-dimensional tissue region
US9433383B2 (en) 2014-03-18 2016-09-06 Monteris Medical Corporation Image-guided therapy of a tissue
US10327830B2 (en) 2015-04-01 2019-06-25 Monteris Medical Corporation Cryotherapy, thermal therapy, temperature modulation therapy, and probe apparatus therefor
US11672583B2 (en) 2015-04-01 2023-06-13 Monteris Medical Corporation Cryotherapy, thermal therapy, temperature modulation therapy, and probe apparatus therefor

Also Published As

Publication number Publication date
CN1477985A (en) 2004-02-25
WO2002043804A1 (en) 2002-06-06
JP2004514510A (en) 2004-05-20
US6618620B1 (en) 2003-09-09
JP4080332B2 (en) 2008-04-23
EP1349612A1 (en) 2003-10-08
EP1349612B1 (en) 2013-08-07
CN1293926C (en) 2007-01-10
AU2002218462A1 (en) 2002-06-11

Similar Documents

Publication Publication Date Title
USRE43901E1 (en) Apparatus for controlling thermal dosing in a thermal treatment system
US20070016039A1 (en) Controlled, non-linear focused ultrasound treatment
US9205282B2 (en) System and method for control and monitoring of conformal thermal therapy
EP2352558B1 (en) System for ultrasound therapy
KR102512194B1 (en) Device for treatment of a tissue
US7806839B2 (en) System and method for ultrasound therapy using grating lobes
US7699780B2 (en) Focused ultrasound system with adaptive anatomical aperture shaping
CN104884127B (en) The multifocal sonication of the high-temperature treatment of focusing ultrasound for using guided by magnetic resonance
JP5819609B2 (en) Image guided focused ultrasound therapy system with motion compensation
US20120191020A1 (en) Uniform thermal treatment of tissue interfaces
JP4828523B2 (en) Assembly for hyperthermia of biological tissue
EP1352387A2 (en) Systems and methods for controlling a phased array focused ultrasound system
KR20140068016A (en) Methods and systems for ultrasound treatment
CN110177599A (en) Overcome sound field and skull heterogeneity
US11524183B1 (en) System, apparatus, and method for delivering ultrasound
Liu et al. Treatment time reduction for large thermal lesions by using a multiple 1D ultrasound phased array system
Shim et al. A sparse-element phased array system based on sequentially multiple focusing for the treatment of large tumors

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FEPP Fee payment procedure

Free format text: PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 12